Registration No. _____________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
REVIV3 PROCARE COMPANY
(Exact name of registrant as specified in its charter)
Delaware | 284 | 47-4125218 | ||
(State
or other jurisdiction of
incorporation or organization) |
(Primary
Standard Industrial
Classification Code Number) |
(I.R.S.
Employer
Identification Number) |
REVIV3 PROCARE COMPANY
The Office
9480 Telstar Avenue., Unit 5
El Monte, CA 90211
Telephone No.: (888) 638-8883
Email: info@reviv3.com
Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
Telephone No.: (302) 658-7581
Email: support@LLCagent.com
(Name, address and telephone number of agent for service)
All Communications to:
William Eilers, Esq.
Eilers Law Group, P.A., P.A.
1000 Fifth Street
Suite 200 – P2
Miami Beach, FL 33139
Telephone No.: (786)273 - 9152
Approximate date of proposed sale to the public: As soon as practicable and from time to time after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ☒ | ||
(Do not check if a smaller reporting company) | |||||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
Proposed | Proposed | |||||||||||||||
Amount to | maximum | maximum | ||||||||||||||
be | offering | aggregate | Amount of | |||||||||||||
registered | price per | offering | registration | |||||||||||||
Title of each class of securities to be registered | (1) | unit (2) | price | fee (3) | ||||||||||||
Common Stock, par value $0.0001 per share (4) | 3,590,532 | $ | 0.05 | $ | 179,526.60 | $ | 22.35 |
(1) | Estimated in accordance with Rule 457(a) of the Securities Act of 1933. |
(2) | Until such time as our common shares are quoted on the OTC Markets, the selling shareholders will sell their shares at the price of up to $0.05 per share. |
(3) | Calculated under Section 6(b) of the Securities Act of 1933 as .0001245 of the aggregate offering price. |
(4) | Represents shares of the registrant's common stock being registered for resale that have been issued to the selling shareholders named in this registration statement. In accordance with Rule 416(a), this registration statement shall also cover an indeterminate number of shares that may be issued and resold resulting from stock splits, stock dividends or similar transactions. |
We hereby amend this registration statement on such date or dates as may be necessary to delay our effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a) may determine.
The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.
PRELIMINARY PROSPECTUS
SUBJECT TO COMPLETION DATED __, 2017
REVIV3 PROCARE COMPANY
3,590,532 Shares of Common Stock
Selling shareholders are offering up to 3,590,532 shares of common stock. The selling shareholders will offer their shares at up to $0.05 per share until our shares are quoted on the OTCQB and, assuming we secure this qualification, thereafter at prevailing market prices or privately negotiated prices. We will not receive proceeds from the sale of shares from the selling shareholders.
There are no underwriting commissions involved in this offering. We have agreed to pay all the costs of this offering. Selling shareholders will pay no offering expenses.
Prior to this offering, there has been no market for our securities. Our common stock is not now listed on any national securities exchange or the NASDAQ stock market, and is not eligible to trade on the OTC Markets. There is no guarantee that our securities will ever trade on the OTC Markets or on any listed exchange.
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”), and will therefore be subject to reduced public company reporting requirements.
This offering is highly speculative and these securities involve a high degree of risk and should be considered only by persons who can afford the loss of their entire investment. See “Risk Factors” beginning on page 19.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
The information in this prospectus is not complete and may be changed. This prospectus is included in the Registration Statement that was filed by us with the Securities and Exchange Commission. We may not sell these securities until the Registration Statement becomes effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
The date of this prospectus is _______, 2017.
The following table of contents has been designed to help you find information contained in this prospectus. We encourage you to read the entire prospectus.
We have not authorized any person to give you any supplemental information or to make any representations for us. You should not rely upon any information about our company that is not contained in this prospectus. Information contained in this prospectus may become stale. You should not assume that the information contained in this prospectus or any prospectus supplement is accurate as of any date other than their respective dates, regardless of the time of delivery of this prospectus, any prospectus supplement or of any sale of the shares. Our business, financial condition, results of operations and prospects may have changed since those dates. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted.
i
PROSPECTUS SUMMARY INFORMATION
This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our securities. You should read the entire prospectus, including “Risk Factors” and the consolidated financial statements and the related notes before making an investment decision.
You should carefully read all information in the prospectus, including the financial statements and their explanatory notes, under the Financial Statements prior to making an investment decision.
PART I
ITEM 1. | BUSINESS |
Organization
REVIV3 PROCARE COMPANY (“us”, “we”, “our”, “Reviv3 Procare”, “Reviv3”, or "the Company") is an emerging growth company, incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC, which was organized on July 31, 2013, in order to launch our hair and skin care product lines for direct sales and distribution in domestic and international markets. Our principal executive office is located at 9480 Telstar Avenue, El Monte, CA 91731. Our telephone number is (888) 638-8883. Our website is www.reviv3.com and is not part of this prospectus.
Our independent registered public accounting firm has issued a “going concern” opinion on our company’s financial statements as of May 31, 2017 and management has concluded the same, meaning that we face uncertainties that our business will not succeed or be viable. Additionally, we will need additional capital or additional financing in the future, and if such financing is not available to us on acceptable terms our business may suffer or fail as a result. From June 1, 2016 to May 31, 2017, we have generated approximately $582,000 in gross revenues, but have a net loss of approximately ($539,000). Our ability to continue operations will require additional capital for the unforeseeable future even if current projections are met.
Business
Reviv3 Procare is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products under various trademarks and brands, and has adopted and used the trademark products for distribution throughout the United States, Canada, Europe and Asia pursuant to the terms of 11 exclusive and non-exclusive distribution agreements with various parties throughout our targeted markets. Our manufacturing operations are outsourced and fulfilled through our co-packers and manufacturing partners. Currently, we produce 8 products with 14 separate sku’s and plan to expand our product lines over the next 12 months.
The personal care product industry boasts roughly 750 companies that generate a combined annual revenue of more than $40 billion. The 50 largest companies comprise almost 70% of the entire revenue. Still, we believe the market will bear competition from small companies able to offer specialized products or cater to particular niche markets.
Makeup, deodorant and nail products comprise 33% of health and beauty care industry revenue. Hair care products generate 25% of personal care product revenue, while creams and lotions comprise 21%. Perfumes, mouthwashes, shaving preparations and other products make up the remaining revenue for beauty skin care product revenues.
1
Our Competitive Strengths
We believe our customers associate the Reviv3 brand as high-quality, premium hair and skin care products that incorporates vitamins and ingredients beneficial for healthy skin and hair. Our brand is reinforced by our selective distribution through high-end salons and spas. We do not sell products in mass market discount outlets which we believe allows us to further control our brand image.
Customer based Product Development. We regularly communicate with key customers and distribution partners throughout our research and development process of new products. We believe our size allows us to be highly agile in addressing the needs of our customers by addressing new products needs in the marketplace.
We believe our core values and corporate vision allows us to attract passionate and motivated employees and partners. We support our employees and associates with a unique performance oriented environment and encourage teamwork across all departments by cross training and workshop programs.
Products
Reviv3 Procare stands for skin health and benefits of healthy scalp and hair follicle. Currently, we sell our Reviv3 Procare hair and skincare products under the Reviv3 Procare brand which includes 8 distinct products. Our Reviv3 System is a series of products which are meant to be used together or stand-alone basis. The hair care products consists of PREP shampoo, PRIME conditioner, and TREAT maintenance care. We also sell an introductory kit which includes all three Reviv3 System products. In addition, we have products dedicated to hair treatment and repair. Currently we have 3 products in our treatment and repair line. BOOST is designed to deliver nutrients and increase circulation to the scalp, MEND Deep Hair Repair Mask for added moisture and PROTECT, a heat protectant product to prevent damage from irons and dryers. We also have a stand-alone Thickening Spray for giving hair more volume and body.
Recent additions to our products lines are our series of baby care products. We’ve recently created a baby shampoo, lotion and body wash. These products will be sold under the brand LANU which we anticipate to launch in January of 2018.
2
THE REVIV3 SYSTEM
PREP – Naturally Based Shampoo
PREP is a gentle sulfate-free daily cleanser/shampoo formulated with protein, vitamin complexes and nutrients to cleanse your scalp from excess oil buildup, environmental residue and toxins that collect on your scalp. PREP is sulfate-free, sodium chloride free, sodium benzoate free, and color safe. PREP is also designed to remove DHT build-up from the hair and scalp. PREP is formulated with herbal extracts, amino acids and glycoprotein to promote hair strength and volume.
3
PRIME – Naturally based Moisture + Conditioner
PRIME Conditioner is a multi-protein, daily use scalp and hair conditioner formulated with botanical extracts, vitamins and peptides designed to moisturize and add elasticity to the scalp and hair. Key ingredients in our PRIME Conditioner are glycoprotein vitamin complex, rice protein and serenoa serrulata fruit extract.
4
TREAT
Reviv3 TREAT Micro Activ3 Treatment
Tri-Peptide complex designed to support nutrient uptake and improve microcirculation to the scalp.
5
TREATMENT AND REPAIR
BOOST provides a Tri-peptide complex consisting of Acetyl Tetrapeptide-3, Trifolim Pratense (clover) flower extract, biotinoyl Tripeptide-1 and Saw Palmetto. Boost is designed to increase microcirculation to the scalp and deliver vitamins and micronutrients to straighten hair follicles and enhance nutrient uptake.
MEND Deep Repair Hair Masque
MEND is a weightless, multi-protein enriched deep penetrating masque designed to strengthen, revive elasticity, repair damage, control frizz and limit chemical stress of all hair types while giving you shine and ease of styling. Formulated with actives to maintain scalp health and support nutrient uptake. MEND deep penetrating masque that strengthens chemically stressed hair, moisturizes, and revives elasticity and natural shine.
6
PROTECT Thermal Protector
PROTECT Thermal Protector is a leave-in conditioner and Thermal Protector spray that detangles and maintains the hair’s moisture and protein. Helps to restore vitality and shine, reduce frizziness and provides thermal protection from heat. Provides UV color protection. PROTECT provides thermal protection from heat styling of blow dryer, flat and curling irons. PROTECT improves moisture, without weight, detangles fine hair and repairs hair damage while increasing strength, while restoring vitality and shine.
Thickening Spray
Our Thickening Spray provides thickness and strength to your hair with no product build-up. Thickening Spray adds volume, texture and shine and is alcohol free. Formulated with actives to maintain scalp health and support nutrient uptake Provides UV color protection. Our Thickening Spray is alcohol free and promotes volume, body and texture for thicker looking hair. We have also formulated the thickening Spray to provide UV color protection. As the spray is virtually weightless, there is little to no build-up.
7
Reviv3 VPro Exfoliate
Reviv3 Exfoliate is a professional use product sold exclusively to salons. Exfoliate is designed as an initial cleanse and exfoliation treatment for removal of excess dirt, oil and residue. Exfoliate is sold in a 6-pack box for 6 separate treatments.
8
LANU
Our line of baby products in currently in the manufacturing process and consists of shampoo, body wash and body lotion. We will be marketing our baby care products under the brand LANU and anticipate launching all three products by January 2018 in United States, Canada and Europe.
These represent our current product lines. However, we are currently developing two new lines that we believe will be launched for the fiscal year end. For more information on products in development, please see Research and Development, below.
Growth Strategy
Expansion of Distribution Channels . Our products are currently selling in various salons, SPAs and beauty supply stores in United States, Italy, Canada and Malaysia primarily through regional distributors. Over time, we intend to expand our distribution channels domestically and in selected international markets which would offer attractive demographics.
Direct to Consumer . We intend to increase our direct to consumer revenues through sales of specifically developed products for the consumer market. LANU, our baby care products is the first of such products. We intend to increase our baby care products as well as introducing other consumer oriented products in FY2018.
Brand Awareness . We intend to increase our brand awareness and brand loyalty through marketing efforts and social media campaigns.
Intellectual Property
We currently hold four trademarks properly registered in their respective jurisdiction. Specifically, we hold a word mark for “Reviv3 Procare” issued on November 1, 2016 as well as trademark for our logo that was registered on October 20, 2015. We also have our original logo trademarked for the Reviv3 Procare brand registered on March 17, 2015. In addition, we have registered the name “Reviv3 Procare” in the Russian Federation, issued on June 13, 2017. We also have a trademark for “The Natural Revolution” with the USPTO. On August 17, 2017, we applied for the mark “Lanu” for our new product line, which application is currently pending.
We do not have any additional trademarks, but as we establish new product lines, we will immediately file for trademark protection. Our formulas are proprietary, but we have not yet taken steps to establish a patent for our processes, formulations or products, generally.
9
Sales and Marketing
Currently, our sales and marketing teams are located in El Monte, California (Corporate Headquarters), Ft. Lee, New Jersey and Toronto, Canada. To date our sales strategy has been through the expansion of our network of local distributors, relying on on-site training of our distributor’s sales teams. As our new products are introduced to the marketplace, we intend using more traditional advertising models such as print ads as well as web based advertising. As we build on our name brand recognition, we intent to develop an internal e-commerce sales and support team to expand our market share in the specific direct to consumer product lines.
It is expected that more and more of the Senior Executive team time will be put into revenues generation efforts as the core team of the company grows and stabilizes in their ability to smoothly scale the company. This is expected to take place in the 2nd and 3rd quarter of fiscal year 2018.
As part of our overall marketing plan, besides traditional methods we intend to provide education to our customers through the use of videos and social media platforms. In addition to focusing on our product lines, we have set forth a mission for better awareness of hair and skin health. Specifically, we will focus on three distinct areas 1) industry training, 2) consumer education and 3) beauty expert endorsements.
Regarding industry training, our goal is to educate service providers and beauty professionals on the benefits of not only our products, but best practices for general health and skin care. We also want to establish protocols for application, use and assessment. We believe our products are only as good as their intended use and part of an everyday healthy regimen.
We strive to educate our customers, and even those who don’t use our products, on a) the effects of the surrounding environment, b) the effects of various treatments and process in the beauty industry; c) how what we consume may affect our skin and hair.
Through these direct interactions and mantras, we intend to increase our brand and develop a captive audience and on-going dialogue with our customers.
Manufacturing and Distribution
All manufacturing of Reviv3 Procare products are performed by co-packers and contract manufacturers. Our contract manufacturers are required to produce our products under the following standards:
● | GMP Drug Manufacturing & ISO 22716 Compliance. | |
● | Compliance with USP and PCPC microbiology standards and guidelines. | |
● | Onsite validated Microbiology Lab. | |
● | Full Stability Testing of original formulation and each subsequent batch. | |
● | Quality control and inspection at each phase of manufacturing and production processes. |
We have no exclusive agreement with any given manufacturer or co-packer, which helps mitigate risk associated with third party delays, failures, or shut downs. Currently, these partners operate in California. So long as the manufacturers and co-packers meet our manufacturing standards, we may explore additional manufacturing and co-packing partners for regional operations depending on market demands and logistical costs.
For customer direct sales, the products are delivered directly from our warehouse to the customer. As our direct to consumer sales grow, management will explore regional warehousing and distribution where demand requires.
10
Customers and Market
The beauty industry is known to be resilient during economic downturns - even faring well during the Great Recession of 2008. Though consumers tend to be more price conscious during those times, they do not stop spending. So in today’s environment of rising per capita incomes the beauty business is booming.
In 2015 the industry generated $56.2 billion in the United States. Hair care is the largest segment with 86,000 locations. Skin care is a close second and growing fast, expected to have revenue of almost $11 billion by 2018. This growth is being driven in part by a generally increasing awareness of the importance of skin care, but also specifically due to an increase in the market for men.
US Beauty Industry Segment | Market Share by Revenue | |||
Hair care | 24 | % | ||
Skin care | 23.7 | % | ||
Cosmetics | 14.6 | % | ||
Perfumes and colognes | 9.5 | % | ||
Deodorants, antiperspirant, feminine cleaning | 8.5 | % | ||
Oral hygiene | 5.6 | % | ||
Other | 14.1 | % |
The major driving forces in the market are outlined below:
● | Organic products & products produced in a sustainable (environmentally conscious) manner. Certainly a niche market for many years, but greater availability of information about the benefits - personal or global - are driving increased growth. |
● | Products and services focused on our aging population. Said plainly - we have a large retired/retiring population, and many of them have money to spend. |
● | Products and services focused on babies and young children. This is frequently related to the organic/sustainable movement above. In particular, millennial moms are willing to pay a premium to make sure their kids have the proper skin protection. |
● | Men’s product and services - this trend is still relatively new but is expected to drive growth for years to come. |
The global market for personal care products is expected to increase between 3.5 and 4.5 percent over the next five years, with a total market value of US$500 billion by 2020. [Growth of global ingredients market outpaces personal care industry, Transparency Market Research, Dec 2015 http://www.transparencymarketresearch.com/pressrelease/organic-personal-care-products.htm ]
Beauty and personal care is a US$465 billion industry globally* Source: The Future of Personal Care in the Globe Asia Pacific, Euromonitor, 2015
Global skin care alone is a US$111 billion market, making up 28% of Beauty and Personal Care sales: www.linkedin.com/pulse/how-consumers-shop-anti-aging-skin-care-market-trends-michelle-skelly
Asia Pacific represents the largest share (29%) of the global personal care products market, with sales fueled mainly by population growth, urbanization and increased per capita spending power. Europe occupies second place, followed by North America. [Asia Pacific to Continue Personal Care Ingredients Market Dominance, Global Market to Reach $11.76 billion by 2023, press release, Europlat.org, http://www.europlat.org/asia-pacific-to-continue-personal-care-ingredients-market-dominance-global-market-to-reach-us11-76-bn-by-2023.htm ]
● | US Beauty Industry Size - $56.2 Billion (2015) [Beauty Industry Analysis 2017] |
o | Hair care 24% ($13.5 Billion) |
o | Skin care 23.7% ($13.4 Billion) |
11
● | US Personal Care Market [Business.com 2_22_17] |
o | $40 billion |
§ | Approx. 750 companies in the segment |
§ | 50 largest companies generate almost 70% of entire revenue |
● | Global Organic Personal Care Market http://www.grandviewresearch.com/industry-analysis/organic-personal-care-market |
o | Current Size – $10.16 billion in 2015. [Organic Personal Care Market Size and Forecast By Product and Trend Analysis from 2014-2025] |
o | Poised to Grow @ a CAGR of 9.8% over the next decade to reach approximately $25.7 billion by 2025 |
According to recent reports, the global organic personal care market is growing at an annual rate of almost 10 percent, with expectations of a market valued at US$15.98 billion by 2020. [Organic Personal Care Market Analysis by Product (Skin Care, Hair Care, Oral Care, Cosmetics) and Segment Forecasts to 2020, Grand View Research, 2015]
● | Luxury Haircare Market (USA ONLY) |
o | Current Size – $459.6 Million (2016) |
● | Global Alopecia (Hair Loss) Market $7.3 Billion (USD) in 2015 http://www.grandviewresearch.com/industry-analysis/alopecia-market |
o | Topical Treatment accounted for over $2.8 Billion (38.4%) |
o | Woman accounted for $4.03 Billion (55.2%) |
o | N. America accounted for $2.49 Billion (34.1%) |
o | Asia Pacific is expected to grow at a lucrative CAGR of 5.3% over the coming eight years. |
Our Advantage
● | Operational advantages |
We believe our operational advantages are found in our Product Development Team’s experience in creating high quality personal care products.
● | Technological advantages |
Over the past 2 years we have worked with various chemists and formulators to develop unique and diverse products utilizing botanical and natural active ingredients. Our products uniqueness is grounded in:
o | how we combine well-known and tested ingredients, and |
o | research and testing in the compounding processes |
12
Our products do not contain pharmaceutical ingredients such as Minoxidil, which in some cases create adverse side effects to users.
● | Cost advantage |
Our in-house design team creates all product packaging designs and marketing materials. We use third party manufacturing facilities to produce our products. Reviv3 Procare products are primarily natural/botanical products that do not contain any pharmaceuticals, our products don’t have to be ingested, nor do they require any invasive procedures.
Customer Service – Return Policies
Return Policy – B2C
We provide a 30-day money back guarantee on any product bought directly from our website, or any digital purchase that is done directly from Reviv3 Procare or a site controlled by Reviv3 Procare (e.g. Professional Amazon Store). We offer full refunds to consumers who are not satisfied with our products for any reason within this period. The refund does not include any upgraded or international shipping charges paid.
Return Policy – B2B
Any product ordered and received by a business (distributor and/or retailer) is guaranteed to arrive in New Condition. Any product received by our distributors in a damaged state, and it is determined to be the fault of Reviv3 Procare and not of the shipping company is offered the option of having replacement product shipped to them in the same manner the original product was shipped at no charge, or to have a credit applied to their account for the full amount of the damaged product. For the return and refund to be granted the business may be asked to provide pictures of the damaged product, and/or to return the damaged product at their cost to Reviv3 Procare facility.
Based on historical data we do not anticipate the cost of returns to be a significant percent of our total sales.
Competition
Hair care and cosmetics markets are highly competitive and although there are many companies offering similar products in the market today, we believe we are able to compete directly with these companies and products by offering quality products which will distinguish our performance and develop brand loyalty.
Top Brands/Market Leaders
● | Nioxin: https://www.nioxin.com/en-US |
● | PhytoWorx |
● | Keranique: https://keranique.com/scalp-stimulating-shampoo-for-thinning-hair?AFID=282&gclid=CM_xkJLq99ICFQJrfgodP0QL_A |
● | Ultrax Labs: https://ultraxlabs.com/products/hair-surge-shampoo |
Large Names
● | Aveda Invati: http://www.aveda.com/hair-care/invati-thinning-hair-solutions |
● | Propecia (Merck & Co.) http://www.merck.com/product/usa/pi_circulars/p/propecia/propecia_ppi.pdf |
● | Bosley: https://www.bosley.com / (Organic/Minoxidil) |
● | Dr. Reddy’s Laboratories – Mintop: http://www.mintop.in/ (Minoxidil) |
Other Competitors
● | Lipogaine: http://www.lipogaine.com/lipogaine-big-3-shampoo/ |
● | Mediceutical Labs: http://www.mediceuticallabs.com/products/ |
● | Just Natural: http://www.justnaturalskincare.com/hair-loss/shampoo-hair-loss.html |
● | Revita: https://www.dslaboratories.com/revita |
● | Majestic Pure: https://majesticpure.com/collections/hair-care |
● | Zenagen: http://www.zenagen.com/ |
13
● | Kevin Murphy: http://kevinmurphy.com.au/ |
● | PURA D'OR https://www.purador.com/ |
● |
Procerin
FoliRevita Neugaine Hairgenics |
Strengths and weaknesses of each competitor
We believe consumers are seeking alternatives to pharmaceutical based products which may cause undesirable side effects. Although the market has many all natural products, there are few companies that dedicate their line of products to high quality and costly ingredients.
This chart provides a visualization of where be we believe Reviv3 products fit into the market compared to our competition in regards to 2 factors, 1) all natural products and 2) intervention, or repairing versus maintenance.
14
This chart provides a visualization of where be we believe Reviv3 products fit into the market compared to our competition in regards to 2 factors, 1) pricing and 2) salon only sales versus mass market sales.
Legal Proceedings
There are currently no ongoing or threatened legal proceedings for the Company or any of its officers and directors.
Research and Development
Currently Reviv3 Procare is in the process of developing and launching two new lines:
Lanu (Brand Name):
Our baby products are created with focus on non-irritant ingredients for gentle cleansing, hydration and avoidance of harsh chemicals. Our initial line will include the Lanu Baby Shampoo, Lanu Ultra-Mild Moisturizing Body Wash and
Lanu Moisturizing Body Lotion.
Lanu Ultra-Mild Tear-Free Shampoo
Our shampoo is made of a natural blend of ingredients specifically designed to be gentle, fragrance free, moisturizing, and non-drying. Lanu contains no sulfates or parabens and is not tested on animals.
Lanu Ultra-Mild Moisturizing Body Wash
Our body wash is created from a natural blend of ingredients designed to be gentle and nourishing to your child’s skin during cleansing. Lanu contains no sulfates or parabens and not tested on animals.
15
Lanu Moisturizing Body Lotion
Our body lotion is created from a natural blend of ingredients designed to maintain skin’s natural balance. Contains no sulfates, parabens and not tested on animals.
● | Gentle & Tear-Free |
● | Hypoallergenic |
● | Sulfate Free |
● | Moisturizing & Soothing |
● | pH Balanced - won’t dry out sensitive skin! |
● | Paraben free |
● | No tears |
● | Contains Aloe to moisturize and soften skin |
● | Not tested on animals and no animal by-products. |
Governmental Regulations and Certifications
Personnel
Full-time Employees
We currently have 8 full time employees, including our officers and directors. There are no formal employment agreements in place.
Consultants
We have currently engaged 6 individuals as outside consultants for sales, marketing and design. No formal agreements are in place. We are an emerging growth company and are in the continued process of developing our products. Although we have generated more than $500,000 in gross revenues for the year ended May 31, 2017, we cannot ensure continued revenues and growth. We have an accumulated deficit and have incurred operating losses since our inception and expect losses to continue during fiscal year 2018. Our independent registered public accounting firm has indicated in their Report that these conditions raise substantial doubt about our ability to continue as a going concern.
Our corporate website is http://reviv3.com. Nothing on our website is a part of this prospectus.
The terms "Our Company" "we," "us" and "our" as used in this prospectus refer to REVIV3 PROCARE COMPANY.
Emerging Growth Company
We are an emerging growth company under the JOBS Act. We shall continue to be deemed an emerging growth company until the earliest of:
a) | the last day of the fiscal year of the issuer during which it had total annual gross revenues of $1,000,000,000 (as such amount is indexed for inflation every five (5) years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more; |
b) | the last day of the fiscal year of the issuer following the fifth anniversary of the date of the first sale of common equity securities of the issuer pursuant to an effective IPO registration statement; |
c) | the date on which such issuer has, during the previous three (3) year period, issued more than $1,000,000,000 in non-convertible debt; or |
d) | the date on which such issuer is deemed to be a ‘large accelerated filer’, as defined in section 240.12b-2 of title 17, Code of Federal Regulations, or any successor thereto. |
16
As an emerging growth company we are exempt from Section 404(b) of Sarbanes Oxley. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures. Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment and the effectiveness of the internal control structure and procedures for financial reporting.
We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
The Offering
As of the date of this prospectus, we had 40,505,047 shares of common stock outstanding.
Selling shareholders are offering up to 3,590,532 shares of common stock. The selling shareholders will offer their shares at up to $0.05 per share until our shares are quoted on the OTC Markets and thereafter at prevailing market prices or privately negotiated prices.
We will pay all expenses of registering the securities, estimated at approximately $40,000.00. We will not receive any proceeds of the sale of these securities.
To be quoted on the OTC Markets, a market maker must file an application on our behalf in order to make a market for our common stock. The current absence of a public market for our common stock may make it more difficult for you to sell shares of our common stock that you own.
Financial Summary
Because this is only a financial summary, it does not contain all the financial information that may be important to you. Therefore, you should carefully read all the information in this prospectus, including the financial statements and their explanatory notes before making an investment decision.
The tables and information below are derived from our audited financial statements for the period from May 31, 2016 to May 31, 2017
Balance Sheets | ||||||||
REVIV3 Procare Company | ||||||||
31 May
2017 |
31 May
2016 |
|||||||
Assets | ||||||||
Total Cash and Cash Equivalents | $ | 416,873 | $ | 369,696 | ||||
Total Current Assets | $ | 613,594 | $ | 694,101 | ||||
Total Property, Plant and Equipment | $ | 7,255 | $ | 3,183 | ||||
Total Other Non-current Assets | $ | 14,849 | $ | 9,455 | ||||
Total Assets | $ | 635,698 | $ | 697,284 | ||||
Liabilities and Equity | ||||||||
Total Liabilities | $ | 83,214 | $ | 65.243 | ||||
Total Equity | $ | 552,484 | $ | 632,041 | ||||
Total Liabilities and Equity | $ | 635,698 | $ | 697,284 |
17
Statements of Operations | ||||||||
REVIV3 Procare Company | ||||||||
For the years ended | ||||||||
May 31,
2017 |
May 31,
2016 |
|||||||
Total Revenue | $ | 582,005 | $ | 475,756 | ||||
Total Cost of Sales | $ | 281,579 | $ | 278,347 | ||||
Gross Profit | $ | 300,426 | $ | 197,409 | ||||
Operating Expenses | $ | 838,632 | $ | 912,089 | ||||
Total Other Income and Expense | $ | (571 | ) | $ | (58,978 | ) | ||
Net Income / (Loss) before Tax | $ | (538,777 | ) | $ | (773,658 | ) | ||
Net Loss | $ | (538,777 | ) | $ | (773,658 | ) | ||
Total Comprehensive Loss | $ | (538,777 | ) | $ | (773,658 | ) |
Shares of common stock offered by selling shareholders: | 3,590,532 | |
Shares of common stock outstanding before the offering: | 40,505,047 | |
Shares of common stock outstanding after the offering: | 40,505,047 | |
Terms of the offering: | The selling shareholders will determine when and how they will sell the securities offered in this prospectus. | |
Trading Market: | There is currently no trading market for our common stock. We intend to apply soon for quotation on the OTC Markets. We will require the assistance of a market-maker to apply for quotation and there is no guarantee that a market-maker will agree to assist us. | |
Use of proceeds: | We will not receive proceeds from the resale of shares by the selling shareholders. | |
Risk Factors: | The common stock offered hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See "Risk Factors" below. |
18
You should carefully consider the risks described below together with all of the other information included in this prospectus before making an investment decision with regard to our securities. The statements contained in or incorporated herein that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, you may lose all or part of your investment. In addition to the other information provided in this prospectus, you should carefully consider the following risk factors in evaluating our business before purchasing any of our common stock.
Risks Related to Our Financial Condition
We have generated minimal revenues from operations, which makes it difficult for us to evaluate our future business prospects and make decisions based on those estimates of our future performance.
As of May 31, 2017, we had generated insufficient revenues. As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Our projections are based upon our best estimates on future growth. Because of the related uncertainties, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in sales, revenues or expenses. If we make poor budgetary decisions as a result of unreliable data, we may never become profitable or incur losses, which may result in a decline in our stock price.
There is substantial doubt about our ability to continue as a going concern and if we are unable to generate significant revenue or secure additional financing we may be unable to implement our business plan and grow our business.
We are an emerging growth company and are in the process of selling and developing our products. Consequently, we have not generated enough revenues as of the date of this prospectus. We have an accumulated deficit and have incurred operating losses since our inception and expect losses to continue during the remainder of fiscal 2018. Our independent registered public accounting firm has indicated in their report that these conditions raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issuance date of this report. The continuation of our business as a going concern is dependent upon the continued financial support from our stockholders.
There is uncertainty regarding our ability to grow our business to a greater extent than we can with our existing financial resources, also described above, without additional financing. We have no agreements, commitments or understandings to secure additional financing at this time. Our long-term future growth and success is dependent upon our ability to continue selling our products and services, generate cash from operating activities and obtain additional financing. There is no assurance that we will be able to continue selling our products and services, generate sufficient cash from operations, sell additional shares of common stock or borrow additional funds. Our inability to obtain additional cash could have a material adverse effect on our ability to grow our business to a greater extent than we can with our existing financial resources, also described above.
19
Expenses required to operate as a public company will reduce funds available to implement our business plan and could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition.
Operating as a public company is more expensive than operating as a private company, including additional funds required to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than planned. We may also be required to hire additional staff to comply with additional SEC reporting requirements. We anticipate that the cost of SEC reporting will be approximately $60,000 annually. Our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our results of operations, cash flow and financial condition. If we fail to meet these requirements, we will be unable to secure a qualification for quotation of our securities on the OTC Markets, or if we have secured a qualification, we may lose the qualification and our securities would no longer trade on the OTC Markets. Further, if we fail to meet these obligations and consequently fail to satisfy our SEC reporting obligations, investors will then own stock in a company that does not provide the disclosure available in quarterly, annual reports and other required SEC reports that would be otherwise publicly available leading to increased difficulty in selling their stock due to our becoming a non-reporting issuer.
Risks Related to Our Business and Industry
We rely on our Chief Executive Officer and a limited number of other key senior officers to operate our business. The loss of any of these individuals could have a material adverse effect on our business.
The loss of our Chief Executive Officer or any of our key senior officers could have a material adverse effect on our business, financial condition and results of operations, particularly if we are unable to hire or relocate and integrate suitable replacements on a timely basis or at all. Further, in order to continue to grow our business, we will need to expand our senior management team. We may be unable to attract or retain these persons. This could hinder our ability to grow our business and could disrupt our operations or otherwise have a material adverse effect on our business.
Our ability to deliver products to our customers in a timely manner and to satisfy our customers’ fulfillment standards are subject to several factors, some of which are beyond our control .
Retailers place great emphasis on timely delivery of our products for specific selling seasons, especially during our third fiscal quarter, and on the fulfillment of consumer demand throughout the year. We cannot control all of the various factors that might affect product delivery to retailers. Vendor production delays, difficulties encountered in shipping from overseas, customs clearance delays, and operational issues with any of the third-party logistics providers we use in certain countries are on-going risks of our business. We also rely upon third-party carriers for our product shipments from our distribution centers to customers. In certain circumstances, we rely on the shipping arrangements our suppliers have made in the case of products shipped directly to retailers from the suppliers. Accordingly, we are subject to risks, including labor disputes, inclement weather, natural disasters, possible acts of terrorism, availability of shipping containers, and increased security restrictions associated with such carriers’ ability to provide delivery services to meet our shipping needs. Failure to deliver products to our retailers in a timely and effective manner, often under special vendor requirements to use specific carriers and delivery schedules, could damage our reputation and brands and result in loss of customers or reduced orders.
Large sophisticated customers may take actions that adversely affect our gross profit and results of operations.
In recent years, we have observed a consumer trend away from traditional grocery and drugstore channels and toward mass merchandisers, which includes super centers and warehouse club stores. In addition, the growth in internet sales both by large traditional retailers and pure online retailers such as Amazon.com has begun to reach a critical mass. This trend has resulted in the increased size and influence of these types of customers. Additionally, certain of these customers source and sell products under their own private label brands that compete with our products. As certain large customers and online retailers grow even larger and become more sophisticated, they may continue to demand lower pricing, special packaging, shorter lead times for the delivery of products, smaller more frequent shipments, or impose other requirements on product suppliers. These business demands may relate to inventory practices, logistics or other aspects of the customer-supplier relationship. If we do not effectively respond to these demands, these customers could decrease their purchases from us. A reduction in the demand for our products by these customers and the costs of complying with their business demands could have a material adverse effect on our business, financial condition and results of operations.
20
We are subject to risks related to our dependence on the strength of retail economies and may be vulnerable in the event of a prolonged economic downturn.
Our business depends on the strength of the retail economies in various parts of the world, primarily in North America and to a lesser extent Europe, Asia and Latin America. These retail economies are affected primarily by factors such as consumer demand and the condition of the retail industry, which, in turn, are affected by general economic conditions and specific events such as natural disasters, terrorist attacks and political unrest. Consumer spending in any geographic region is generally affected by a number of factors, including local economic conditions, government actions, inflation, interest rates, energy costs, unemployment rates, gasoline prices and consumer confidence, all of which are beyond our control. Consumer purchases of discretionary items tend to decline during recessionary periods, when disposable income is lower, and may impact sales of our products. As a result of a prolonged recovery from the most recent global recession, many consumers have less money for discretionary purchases as a result of job losses, foreclosures, bankruptcies, reduced access to credit, recent increases in U.S. payroll and income taxes, the expiration of extended unemployment and food stamp benefits in the U.S. and similar such government program curtailments in certain European countries, a lack of clarity for many U.S. consumers regarding their personal health care costs, and slow-to-recover housing prices, among other things. The modest and protracted recovery from the recession in the United States, the United Kingdom, Canada, Mexico or any of the other countries in which we conduct significant business may continue to cause significant readjustments in both the volume and mix of our product sales, which could materially and adversely affect our business, financial condition and results of operations.
The impact of these external factors and the extent to which they may continue is difficult to predict, and one or more of the factors could adversely impact our business. In recent years, the retail industry in the U.S., and increasingly elsewhere, has been characterized by intense competition among retailers and the growth in internet sales both by traditional retailers and pure online retailers such as Amazon.com. Because such competition, particularly when weak retail economies exist, can cause retailers to struggle or fail, we must continuously monitor, and adapt to changes in, the profitability, creditworthiness and pricing policies of our customers. A deterioration of any of our key retail economies, could have a material adverse effect on our business, financial condition and results of operations.
Our operating results may be adversely affected by foreign currency exchange rate fluctuations.
Our functional currency is the U.S. Dollar. Changes in the relation of other foreign currencies to the U.S. Dollar will affect our sales and profitability and can result in exchange losses because the Company has customers and sales channels outside the United States. Such transactions include sales, certain inventory purchases and operating expenses. Accordingly, foreign operations will continue to expose us to foreign currency fluctuations, both for purposes of actual conversion and financial reporting purposes. Additionally, we purchase a substantial amount of our products from Chinese manufacturers. During fiscal years 2016 and 2015, the Chinese Renminbi depreciated against the U.S. Dollar. However, recent trends show the Renminbi appreciating against the U.S. Dollar. Although our purchases from China are in U.S. Dollars, if the Chinese Renminbi continues to appreciate against the U.S. Dollar, the costs of our products will likely rise over time because of the impact the fluctuations will have on our suppliers, and we may not be able to pass on any or all of these price increases to our customers.
The impact of future exchange rate fluctuations on our results of operations cannot be accurately predicted. Accordingly, there can be no assurance that U.S. Dollar foreign exchange rates will be stable in the future or that fluctuations in foreign currency markets will not have a material adverse effect on our business, financial condition and results of operations.
We are dependent on third-party manufacturers, most of which are located in the Far East, and any inability to obtain products from such manufacturers could have a material adverse effect on our business, financial condition and results of operations.
All of our products are manufactured by unaffiliated companies, most of which are in the Far East, principally in China. This concentration exposes us to risks associated with doing business globally, including: changing international political relations; labor availability and cost; changes in laws, including tax laws, regulations and treaties; changes in labor laws, regulations and policies; changes in customs duties and other trade barriers; changes in shipping costs; currency exchange fluctuations; local political unrest; an extended and complex transportation cycle; the impact of changing economic conditions; and the availability and cost of raw materials and merchandise. The political, legal and cultural environment in the Far East is rapidly evolving, and any change that impairs our ability to obtain products from manufacturers in that region, or to obtain products at marketable rates, could have a material adverse effect on our business, financial condition and results of operations.
21
With most of our manufacturers located in the Far East, our production lead times are relatively long. Therefore, we must commit to production in advance of customer orders. If we fail to forecast customer or consumer demand accurately, we may encounter difficulties in filling customer orders on a timely basis or in liquidating excess inventories. Any of these results could have a material adverse effect on our business, financial condition and results of operations.
Historically, labor in China has been readily available at relatively low cost as compared to labor costs in North America, Europe and other countries. China has experienced rapid social, political and economic change in recent years. There is no assurance labor will continue to be available in China at costs consistent with historical levels or that changes in labor or other laws will not be enacted which would have a material adverse effect on the cost of products manufactured in China. Many of our suppliers in China continue to experience labor shortages, which could result in future supply delays and disruptions and have resulted in a substantial increase in labor costs over the last three fiscal years. Similarly, evolving government labor regulations and associated compliance standards could cause our product costs to rise or could cause manufacturing partners we rely on to exit the business. This could have an adverse impact on product availability and quality. The Chinese economy has experienced rapid expansion and highly fluctuating rates of inflation. Higher general inflation rates will require manufacturers to continue to seek increased product prices. During fiscal years 2014 and 2012, the Chinese Renminbi appreciated against the U.S. Dollar approximately 3 and 4 percent, respectively. During fiscal year 2013, the Chinese Renminbi remained relatively flat against the U.S. Dollar. If the Chinese Renminbi appreciates with respect to the U.S. Dollar in the future, the Company may experience cost increases on such purchases, and this can adversely impact profitability. Future interventions by China may result in further currency appreciation and increase our product costs over time. The Company may not be successful at implementing customer pricing or other actions in an effort to mitigate the related effects of the product cost increases. Although China currently enjoys “most favored nation” trading status with the U.S., the U.S. government has in the past proposed to revoke such status and to impose higher tariffs on products imported from China. There is no assurance that our business will not be affected by any of the aforementioned risks, each of which could have a material adverse effect on our business, financial condition and results of operations.
High costs of raw materials and energy may result in increased cost of goods sold and certain operating expenses and adversely affect our results of operations and cash flow.
Significant variations in the costs and availability of raw materials and energy may negatively affect our results of operations. Our suppliers purchase significant amounts of metals and plastics to manufacture our products. In addition, they also purchase significant amounts of electricity to supply the energy required in their production processes. Changes in the cost of fuel as a result of Middle East tensions and related political instabilities may continue to drive up fuel prices resulting in higher transportation prices and product costs. The cost of these raw materials and energy, in the aggregate, represents a significant portion of our cost of goods sold and certain operating expenses. Our results of operations could be adversely affected by future increases in these costs. We have had some success in implementing price increases to our customers or passing on product cost increases by moving customers to newer products with enhancements that justify higher prices, and we intend to continue these efforts. We can make no assurances that these efforts will be successful in the future or will materially offset the cost increases we may incur.
Our projections of product demand, sales and net income are highly subjective in nature and our future sales and net income could vary in a material amount from our projections.
From time to time, we may provide projections to our shareholders, lenders, investment community, and other stakeholders of our future sales and net income. Since we do not require long-term purchase commitments from our major customers and the customer order and ship process is very short, it is difficult for us to accurately predict the demand for many of our products, or the amount and timing of our future sales and related net income. Our projections are based on management’s best estimate of sales using historical sales data and other information deemed relevant. These projections are highly subjective since sales to our customers can fluctuate substantially based on the demands of their retail customers and due to other risks described in this report. Additionally, changes in retailer inventory management strategies could make our inventory management more difficult. Because our ability to forecast product demand and the timing of related sales includes significant subjective input, our future sales and net income could vary materially from our projections.
22
To compete successfully, we must develop and introduce a continuing stream of innovative new products to meet changing consumer preferences.
Our long-term success in the competitive retail environment depends on our ability to develop and commercialize a continuing stream of innovative new products that meet changing consumer preferences and take advantage of opportunities sooner than our competition. We face the risk that our competitors will introduce innovative new products that compete with our products. Our core initiatives include fostering our culture of innovation and new product development, enhancing and extending our existing product categories and developing new allied product categories. There are numerous uncertainties inherent in successfully developing and commercializing new products on a continuing basis and new product launches may not deliver expected growth in sales or operating income. If we are unable to develop and introduce a continuing stream of new products, it may have an adverse effect on our business, financial condition and results of operations.
Our operating results may be adversely affected by trade barriers, exchange controls, expropriations, and other risks associated with foreign operations.
The economies of foreign countries important to our operations, including countries in Asia, Europe and Latin America, could suffer slower economic growth or economic, social and / or political instability or hyperinflation in the future. Our international operations in countries in Asia, Europe and Latin America, including manufacturing and sourcing operations (and the international operations of our customers), are subject to inherent risks which could adversely affect us, including, among other things:
● | protectionist policies restricting or impairing the manufacturing, sales or import and export of our products; |
● | new restrictions on access to markets; |
● | lack of developed infrastructure; |
● | inflation (including hyperinflation) or recession; |
● | changes in, and the burdens and costs of compliance with, a variety of foreign laws and regulations, including tax laws, accounting standards, environmental laws and occupational health and safety laws; |
● | social, political or economic instability; |
● | acts of war and terrorism; |
● | natural disasters or other crises; |
● | reduced protection of intellectual property rights in some countries; |
● | increases in duties and taxation; |
● | restrictions on transfer of funds or exchange of currencies; |
● | currency devaluations; |
● | expropriation of assets; and |
● | other adverse changes in policies, including monetary, tax or lending policies, encouraging foreign investment or foreign trade by our host countries. |
23
Should any of these events occur, our ability to sell or export our products or repatriate profits could be impaired, we could experience a loss of sales and profitability from our international operations, and / or we could experience a substantial impairment or loss of assets, any of which could materially and adversely affect our business, financial condition and results of operations.
Information security breaches and any related operational interruptions could have a material adverse effect on our operations and profitability.
Information systems require constant updates to their security policies and hardware systems to reduce the risk of unauthorized access, malicious destruction of data or information theft. We rely on commercially available systems, software, tools, and monitoring to provide security for processing, transmission and storage of confidential information. Improper activities by third parties, advances in computer and software capabilities and encryption technology, new tools and discoveries and other events or developments may facilitate or result in a compromise or breach of our computer systems, some of which may go undetected for extended periods.
Any such compromise or breach could cause interruptions in our operations, damage to our reputation and might require us to spend significant management time and money investigating the event and dealing with local and federal law enforcement. In addition, we could become the subject of litigation and various claims from our customers, employees, suppliers, service providers, and shareholders. Regardless of the merits and ultimate outcome of these matters, litigation and proceedings of this type are expensive to respond to and defend, and we could be forced to devote substantial resources and time responding to and defending them, which could have a material adverse effect on our business, financial condition and results of operations.
Potential changes in laws, including tax laws, and the costs and complexities of compliance with such laws could have an adverse impact on our business.
The impact of future legislation in the U.S. or abroad, including such things as employment and health insurance laws, climate change related legislation, tax legislation, regulations or treaties, including any that would affect the companies or subsidiaries that comprise our consolidated group, is always uncertain. The U.S. Congress continues to consider certain proposed changes in the tax laws, and new energy and environmental legislation that, if enacted, may increase our costs of doing business.
We rely on third-party delivery services to deliver our products to our customers on a timely and consistent basis, and any deterioration in our relationship with any one of these third parties or increases in the fees that they charge could harm our reputation and adversely affect our business and financial condition.
We rely on third parties for the shipment and delivery of our products and we cannot be sure that we will have relationships with these third parties on terms that are favorable to us, or at all. Shipping costs may increase over time, which could harm our business, prospects, financial condition and results of operations by increasing our costs of doing business and resulting in reduced gross margins. In addition, if our relationships with these third parties are terminated or impaired, or if these third parties are unable to deliver products for us, whether due to labor shortage, slow down or stoppage, deteriorating financial or business condition, responses to terrorist attacks or for any other reason, we would be required to locate alternative carriers for the shipment of products to our customers. Changing carriers could have a negative effect on our business and operating results due to package tracking and delays in order processing and product delivery. We could be unable to engage alternative carriers on a timely basis, upon terms favorable to us, or at all.
Our product design and technology are not protected by intellectual property right in the U.S.
Our success will depend in part on our ability to protect our proprietary rights. Although we have trademarked our logo and name, the products that we sell are not currently protected by any patent or other intellectual property rights in the U.S. or abroad. The products are produced and manufactured by third parties and include ingredients that may not be unique to our products. As a result, the design and technical features of our products are vulnerable to being copied or imitated by U.S. and, potentially, international competitors. Our competitors may have or develop equivalent or superior manufacturing and design skills, and may develop an enhancement that will be patentable or otherwise protected from duplication by others. These events could have a material adverse effect on our business, prospects, results of operations and financial condition.
24
Our international operations will require us to obtain financing in various jurisdictions.
We will operate in the United States and other foreign countries, which creates financing challenges. These challenges include navigating local legal and regulatory requirements associated with obtaining debt or equity financing in the respective foreign jurisdictions in which we operate. In the event that we are not able to obtain financing on satisfactory terms in any of these jurisdictions, it could significantly impair its ability to run its foreign operations on a cost-effective basis or to grow such operations. Failure to manage such challenges may adversely affect our business and results of operations.
International sales and operations are subject to applicable laws relating to trade, export controls and foreign corrupt practices, the violation of which could adversely affect operations.
We will comply with all applicable international trade, customs, export controls, and economic sanctions laws and regulations of the United States and other countries. We are also subject to the Foreign Corrupt Practices Act and other anti-bribery laws that generally bar bribes or unreasonable gifts to foreign governments or officials. Changes in trade sanctions laws may restrict our business practices, including cessation of business activities in sanctioned countries or with sanctioned entities, and may result in modifications to compliance programs. Violation of these laws or regulations could result in sanctions or fines and could have a material adverse effect on our financial condition, results of operations and cash flows.
We may in the future be subject to intellectual property rights disputes, which could reduce our ability to compete effectively and harm our business and results of operations.
Other companies may own, develop, or acquire intellectual property rights that could prevent, limit, or interfere with our ability to provide our products and services. One or more of these companies, which could include our competitors, could make claims against us alleging infringement of their intellectual property rights. Any intellectual property claims, with or without merit, could be time-consuming and expensive to litigate or settle and could significantly divert management resources and attention from our business.
If we were unable to successfully defend against claims against us alleging infringement of intellectual property rights, we may be required to pay monetary damages, stop using the technology, and pay a license fee to use the technology, or develop alternative non-infringing technology. If we have to obtain a license for the infringing technology, it may not be available on reasonable terms, if at all. Developing alternative non-infringing technology could require significant effort and expense. If we cannot license or develop alternative technology for the infringing aspects of our business, we may be forced to limit our product and service offerings. Any of these results could reduce our ability to compete effectively and harm our business and results of operations.
Damage claims against our products could reduce our sales and revenues.
If any of our products are found to cause injury or damage, the Company could suffer financial damages. We have not had significant claims for damages or losses from our products to date. The Company does not carry product liability insurance.
A partially or completely uninsured claim, if successful and of significant magnitude, could have a material adverse effect on our business, prospects, results of operations or financial condition.
25
The purchase of many of our products is discretionary, and may be particularly affected by adverse trends in the general
economy; therefore, challenging economic conditions may make it difficult for us to generate revenue.
Our business is affected by general economic conditions since our products are discretionary and we depend, to a significant extent, upon a number of factors relating to discretionary consumer spending. These factors include economic conditions and perceptions of such conditions by consumers, employment rates, the level of consumers' disposable income, business conditions, interest rates, consumer debt levels, and availability of credit. There can be no assurance that consumer spending on the products we sell, will not be adversely affected by changes in general economic conditions.
Risks Related To Our Management and Personnel
Should we not be able to find capable management, our financial condition will be negatively impacted.
Our future depends on finding management that can maintain U.S. operations including creation of said operations. The services are critical to the management of our business and operations in the U.S. We must find competent and experienced personnel; our operational goals and strategies may be adversely affected, which will negatively affect our potential revenues.
We will incur additional costs and management time related expenses pertaining to SEC reporting obligations and SEC compliance matter and our management has no experience in such matters.
Our officers and directors, Jeff Toghraie, Ivan Klarich, Chris Go, and Nancy Hundt, are responsible for managing us, including compliance with SEC reporting obligations and maintaining disclosure controls and procedures and internal control over financial reporting. These public reporting requirements and controls are new to the above and at times will require us to obtain outside assistance from legal, accounting, or other professionals that will increase our costs of doing business. Should we fail to comply with SEC reporting and internal controls and procedures, we may be subject to securities law violations that may result in additional compliance costs or costs associated with SEC judgments or fines, both of which will increase our costs and negatively affect our potential profitability and our ability to conduct our business.
Because we do not have an audit or compensation committee, shareholders will have to rely on our board of directors who is not independent to perform these functions.
We do not have an audit or compensation committee or board of directors as a whole that is composed of independent directors. These functions are performed by our officers and directors, Jeff Toghraie, Ivan Klarich, Chris Go, an Nancy Hundt. Because our directors are not independent, there is a potential conflict between their and/or our interests and our shareholders’ interests since the above will participate in discussions concerning management compensation and audit issues that may be affect management decisions. Until we have an audit committee or independent directors, there may be less oversight of management decisions and activities and little ability for minority shareholders to challenge or reverse those activities and decisions, even if they are not in the best interests of minority shareholders.
Because we lack certain internal controls over financial reporting in that we do not have an audit committee and our Board of Directors has no technical knowledge of U.S. GAAP and internal control of financial reporting and relies upon the Company's financial personnel to advise the Board on such matters, we are subject to increased risk related to financial statement disclosures.
We lack certain internal controls over financial reporting in that we do not have an audit committee and our Board of Directors has no technical knowledge of U.S. GAAP and internal control of financial reporting and relies upon the Company's financial personnel to advise the Board on such matters. Accordingly, we are subject to increased risk related to financial statement disclosures.
26
Risks Related to the Market for Our Common Stock
We may, in the future, issue additional securities, which would reduce investors’ percent of ownership and may dilute our share value.
Our Articles of Incorporation authorize us to issue 100,000,000 shares of common stock and 20,000,000 shares of blank check preferred stock. As of the date of this prospectus, we had 40,505,047 shares of common stock and no preferred shares outstanding. Accordingly, we may issue up to an additional 59,494,953 shares of common stock and 20,000,000 shares of blank check preferred stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis including for services or acquisitions or other corporate actions that may have the effect of diluting the value of the shares held by our stockholders, and might have an adverse effect on any trading market for our common stock. Our board of directors may designate the rights, terms and preferences of our authorized but unissued preferred shares at its discretion including conversion and voting preferences without notice to our shareholders.
We are an "emerging growth company," and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.
We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five (5) years, although we could lose that status sooner if our revenues exceed one billion dollars ($1,000,000,000), if we issue more than one billion dollars ($1,000,000,000), in non-convertible debt in a three year period, or if the market value of our common stock held by non-affiliates exceeds seven hundred-million dollars ($700,000,000) as of any December 31 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
Our common stock is not currently quoted or listed and may never be quoted or listed by the OTC Markets or any other listing or quotation service and if listed, no market may ever develop for our common stock, or if developed, may not be sustained in the future. Investors may have difficulty in reselling their shares due to the lack of market or state Blue Sky laws.
Our common stock is currently not quoted on any market. No market may ever develop for our common stock, or if developed, may not be sustained in the future. The holders of our shares of common stock and persons who desire to purchase them in any trading market that might develop in the future should be aware that there might be significant state law restrictions upon the ability of investors to resell our shares. Accordingly, even if we are successful in having the shares available for trading on the OTC Markets, investors should consider any secondary market for our common shares to be a limited one. We intend to seek coverage and publication of information regarding the company in an accepted publication, which permits a "manual exemption." This manual exemption permits a security to be distributed in a particular state without being registered if the company issuing the security has a listing for that security in a securities manual recognized by the state. However, it is not enough for the security to be listed in a recognized manual. The listing entry must contain (1) the names of issuers, officers, and directors, (2) an issuer's balance sheet, and (3) a profit and loss statement for either the fiscal year preceding the balance sheet or for the most recent fiscal year of operations. We may not be able to secure a listing containing all of this information. Furthermore, the manual exemption is a non-issuer exemption restricted to secondary trading transactions, making it unavailable for issuers selling newly issued securities. Most of the accepted manuals are those published in Standard and Poor's, Moody's Investor Service, Fitch's Investment Service, and Best's Insurance Reports, and many states expressly recognize these manuals. A smaller number of states declare that they “recognize securities manuals” but do not specify the recognized manuals. The following states do not have any provisions and therefore do not expressly recognize the manual exemption: Alabama, California, Georgia, Illinois, Kentucky, Louisiana, Montana, South Dakota, Tennessee, Vermont and Wisconsin.
27
Accordingly, our common shares should be considered totally illiquid, which inhibits investors’ ability to resell their shares.
We will be subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.
The SEC has adopted regulations which generally define so-called “penny stocks” to be an equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. We anticipate that our common stock will become a “penny stock”, and we will become subject to Rule 15g-9 under the Exchange Act, or the “Penny Stock Rule”. This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers. For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our common shares and may affect the ability of purchasers to sell any of our common shares in the secondary market.
For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.
We do not anticipate that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.
Sales of our common stock under Rule 144 could reduce the price of our stock.
None of our outstanding common shares are currently eligible for resale under Rule 144. In general, persons holding restricted securities in a Securities & Exchange Commission reporting company, including affiliates, must hold their shares for a period of at least six (6) months, may not sell more than one percent (1%) of the total issued and outstanding shares in any ninety (90) day period, and must resell the shares in an unsolicited brokerage transaction at the market price. If substantial amounts of our common stock become available for resale under Rule 144, prevailing market prices for our common stock will be reduced.
If in the future we are not be required to continue filing reports under Section 15(d) of the Securities Exchange Act of 1934, for example because we have less than three hundred shareholders of record at the end of the first fiscal year in which this registration statement is declared effective, and we do not file a Registration Statement on Form 8-A upon the occurrence of such an event, our common shares can no longer be quoted on the OTC Quotation Board, which could reduce the value of your investment.
Upon effectiveness of this registration statement, we will be subject to the 15(d) reporting requirements according to the Securities Exchange Act of 1934. We are required to file the necessary reports in the fiscal year that the registration statement is declared effective. After that fiscal year and provided that we have less than three hundred (300) shareholders, we are not required to file these reports. If the reports are not filed, the investors will have reduced information about us including about our business, plan of operations and financial condition. In addition, as a filer subject to Section 15(d) of the Exchange Act, we are not required to prepare proxy or information statements; our common stock will not be subject to the protection of the going private regulations; we will be subject to only limited portions of the tender offer rules; our officers, directors, and more than ten (10%) percent shareholders are not required to file beneficial ownership reports about their holdings of our common shares; that these persons will not be subject to the short-swing profit recovery provisions of the Exchange Act; and that more than five percent (5%) holders of classes of your equity securities will not be required to report information about their ownership positions in the securities.
28
There is no assurance of a public market or that our common stock will ever trade on a recognized stock exchange. Therefore, you may be unable to liquidate your investment in our stock.
There is no established public trading market for our common stock. Our shares have not been listed or quoted on any exchange or quotation system. There can be no assurance that a market maker will agree to file the necessary documents with FINRA, nor can there be any assurance that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.
Because we do not expect to pay dividends for the foreseeable future, investors seeking cash dividends should not purchase our common stock.
We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future. Our payment of any future dividends will be at the sole discretion of our Board of Directors after considering whether we have generated sufficient revenues, our financial condition, operating results, cash needs, growth plans and other factors. Accordingly, investors that are seeking cash dividends should not purchase our common stock.
As an issuer of “penny stock” the protection provided by the federal securities laws relating to forward looking statements does not apply to us.
Although the federal securities law provides a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws, this safe harbor is not available to issuers of penny stocks. As a result, if we are a penny stock we will not have the benefit of this safe harbor protection in the event of any claim that the material provided by us contained a material misstatement of fact or was misleading in any material respect because of our failure to include any statements necessary to make the statements not misleading.
Special Information Regarding Forward Looking Statements
Some of the statements in this prospectus are “forward-looking statements.” These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under “Risk Factors.” The words “believe,” “expect,” “anticipate,” “intend,” “plan,” and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a non-reporting issuer. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with an initial public offering.
Not applicable. We will not receive any proceeds from the sale of shares offered by the selling shareholders.
29
DETERMINATION OF OFFERING PRICE
Our management has determined the offering price for the selling shareholders' shares. The price of the shares we are offering were arbitrarily determined. We have no agreement, written or oral, with our selling shareholders about this price. Based upon oral conversations with our selling shareholders, we believe that none of our selling shareholders disagree with this price. The offering price bears no relationship whatsoever to our assets, earning, book value or other criteria of value. The factors considered were:
● | Our growth potential; and |
● | The price we believe a purchaser is willing to pay for our stock |
The offering price does not bear any relationship to our assets, results of operations, or book value, or to any other generally accepted criteria of valuation. Prior to this offering, there has been no market for our securities.
Not applicable. We are not offering any shares in this registration statement. All shares are being registered on behalf of our selling shareholders.
The selling security holders named below are selling the securities. The table assumes that all of the securities will be sold in this offering. However, any or all of the securities listed below may be retained by any of the selling security holders, and therefore, no accurate forecast can be made as to the number of securities that will be held by the selling security holders upon termination of this offering.
We believe that the selling security holders listed in the table have sole voting and investment powers with respect to the securities indicated. We will not receive any proceeds from the sale of the securities by the selling security holders. None of our selling security holders is or is affiliated with a broker-dealer. All selling security holders may be deemed underwriters. The percentages below are based upon 40,505,047 common shares outstanding.
Our selling shareholders hold an aggregate of 3,590,532 common shares as reflected in the chart below. We are not registering common shares held directly or indirectly by our officers or directors and persons we deem affiliates of the Company
We relied on Section 4(2) of the Securities Act of 1933, as amended for the offer and sale of the securities in the chart below. We believe that Section 4(2) was available because:
● | Each investor had a pre-existing relationship with one or more of: (i) our chief executive officer, president and director, Mr. Jeff Toghraie. |
● | None of these issuances involved underwriters, underwriting discounts or commissions. |
● | Restrictive legends were and will be placed on all certificates issued as described above. |
● | The offer and sale of the securities did not involve general solicitation or advertising. |
● | The distributions were made only to investors who were sophisticated enough to evaluate the risks of the investment. |
In connection with the foregoing transactions, we provided the following to all investors:
● | Access to all of our books and records. |
● | Access to all material contracts and documents relating to our operations. |
30
● | The opportunity to obtain any additional information, to the extent we possessed such information, necessary to verify the accuracy of the information to which the investors were given access. |
Name of Shareholder |
Total # of Shares Owned |
# of Shares Registered |
Remaining # Shares if All Registered Are Sold [1] |
% Before Offering |
% After
Offering
|
|||||||||||||||
Sheri Amirjahed | 80,000 | 80,000 | 0 | 0.20 | % | 0.00 | % | |||||||||||||
Axon Capital Management | 3,600,000 | 250,000 | 3,350,000 | 8.89 | % | 8.44 | % | |||||||||||||
Bagheri Family Trust, Kaveh & Soraya Bolandgray Bagheri | 100,000 | 100,000 | 0 | 0.25 | % | 0.00 | % | |||||||||||||
Hamid Bahmei | 80,000 | 80,000 | 0 | 0.20 | % | 0.00 | % | |||||||||||||
Abbas Bolandgray | 80,000 | 80,000 | 0 | 0.20 | % | 0.00 | % | |||||||||||||
Azar Bolandgray | 20,000 | 20,000 | 0 | 0.05 | % | 0.00 | % | |||||||||||||
Leila Bolandgray | 40,650 | 40,650 | 0 | 0.10 | % | 0.00 | % | |||||||||||||
Abby Bonilla | 12,000 | 12,000 | 0 | 0.03 | % | 0.00 | % | |||||||||||||
Luciana Ercasi Carlet | 16,260 | 16,260 | 0 | 0.04 | % | 0.00 | % | |||||||||||||
Charter Capital Partners | 3,600,000 | 300,000 | 3,300,000 | 8.89 | % | 8.32 | % | |||||||||||||
Philip Coca | 61,157 | 61,157 | 0 | 0.15 | % | 0.00 | % | |||||||||||||
Davis Elen Advertising | 887,239 | 100,000 | 787,239 | 2.19 | % | 1.98 | % | |||||||||||||
Ibrahim Sahu Derbent | 32,520 | 32,520 | 0 | 0.08 | % | 0.00 | % | |||||||||||||
DRS, LLC | 898,838 | 100,000 | 798,838 | 2.22 | % | 2.01 | % | |||||||||||||
Bernadette Eckard Maloney | 400,000 | 100,000 | 300,000 | 0.99 | % | 0.76 | % | |||||||||||||
Jorge B. Gutierrez Ercasi | 200,000 | 50,000 | 150,000 | 0.49 | % | 0.38 | % | |||||||||||||
Manuel Gonzales | 10,000 | 10,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Daniel Govea | 860,000 | 860,000 | 0 | 2.12 | % | 0.00 | % | |||||||||||||
Pamela Goyal | 58,979 | 58,979 | 0 | 0.15 | % | 0.00 | % | |||||||||||||
Beril Gutierrez | 294,500 | 60,000 | 234,000 | 0.73 | % | 0.59 | % | |||||||||||||
Fayez Henein | 10,000 | 10,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Mary Henein | 10,000 | 10,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Nancy Hundt | 2,600,000 | 100,000 | 2,500,000 | 6.42 | % | 6.30 | % | |||||||||||||
Intrepid Global Advisors | 9,334,000 | 100,000 | 9,234,000 | 23.04 | % | 23.27 | % | |||||||||||||
Nelmettin Alper Karacadag | 200,000 | 50,000 | 150,000 | 0.49 | % | 0.38 | % | |||||||||||||
Zehra Belgin Karacadag | 200,000 | 50,000 | 150,000 | 0.49 | % | 0.38 | % | |||||||||||||
Zolio Gutierrez Martinez | 24,390 | 24,390 | 0 | 0.06 | % | 0.00 | % | |||||||||||||
Guillermo Mena | 10,000 | 10,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Robert A Lay& Mina Javid | 120,000 | 120,000 | 0 | 0.30 | % | 0.00 | % | |||||||||||||
Robert A Lay | 48,076 | 48,076 | 0 | 0.12 | % | 0.00 | % | |||||||||||||
Patrick Morris | 18,000 | 18,000 | 0 | 0.04 | % | 0.00 | % | |||||||||||||
Arturo Nava | 20,000 | 20,000 | 0 | 0.05 | % | 0.00 | % | |||||||||||||
Soraya Sabetian | 60,000 | 60,000 | 0 | 0.15 | % | 0.00 | % | |||||||||||||
Richard Serafin | 10,000 | 10,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Stephen Salinger Trust of Salinger Solo 401K Trust Stephen Salinger, TTEE | 200,000 | 100,000 | 100,000 | 0.49 | % | 0.25 | % | |||||||||||||
Universal22, Inc. | 30,000 | 30,000 | 0 | 0.07 | % | 0.00 | % | |||||||||||||
Sunook Park | 51,000 | 10,000 | 41,000 | 0.13 | % | 0.10 | % | |||||||||||||
Jalil & Lili Riazi JTWROS | 167,170 | 120,000 | 47,170 | 0.41 | % | 0.12 | % | |||||||||||||
Tital HG, LLC | 1,025,709 | 100,000 | 925,709 | 2.53 | % | 2.33 | % | |||||||||||||
Sara Halyo Topuz | 20,000 | 20,000 | 0 | 0.05 | % | 0.00 | % | |||||||||||||
Shircoo, Inc. | 13,385,000 | 100,000 | 13,285,000 | 33.05 | % | 33.48 | % | |||||||||||||
John Lou | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Dexter Go | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Joel Go | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Jeremy Limsenben | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Jeff Brown | 9,000 | 9,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Robert Ukropina | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Dale Winson | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Coco Hou | 7,000 | 7,000 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
Jason Sabaugh | 7,500 | 7,500 | 0 | 0.02 | % | 0.00 | % | |||||||||||||
TOTAL | 38,943,988 | 3,590,532 | 35,353,456 | 96.15 | % | 87.28 | % |
[1] | Assuming that all 3,590,532 shares being registered are sold. |
[2] | Based 40,505,047 common shares outstanding. |
31
All shares vested immediately and common shares were issued bearing a restrictive legend.
No persons acquiring the shares covered by this registration statement had any rights attached to the shares purchased by the selling shareholders, including rights such as registration rights.
Holders of Record
We have 75 shareholders of record; including officers and directors of the Company.
Offers and Sales of Securities
We currently do not intend to and may not be able to qualify securities for resale in other states which require shares to be qualified before they can be resold by our shareholders.
Our common stock is currently not quoted on any market. No market may ever develop for our common stock, or if developed, may not be sustained in the future. Accordingly, our shares should be considered totally illiquid, which inhibits investors’ ability to resell their shares.
Selling shareholders are offering up to 3,590,532 shares of common stock. The selling shareholders will offer their shares at up to $0.05 per share until our shares are quoted on the OTCQB and thereafter at prevailing market prices or privately negotiated prices. We will not receive proceeds from the sale of shares from the selling shareholders. There is no guarantee that our stock will ever be quoted on the OTCQB.
The securities offered by this prospectus will be sold by the selling shareholders. Selling shareholders in this offering may be considered underwriters. We are not aware of any underwriting arrangements that have been entered into by the selling shareholders. The distribution of the securities by the selling shareholders may be effected in one or more transactions that may take place in the over-the-counter market, including broker's transactions or privately negotiated transactions.
The selling shareholders may pledge all or a portion of the securities owned as collateral for margin accounts or in loan transactions, and the securities may be resold pursuant to the terms of such pledges, margin accounts or loan transactions. Upon default by such selling shareholders, the pledge in such loan transaction would have the same rights of sale as the selling shareholders under this prospectus. The selling shareholders may also enter into exchange traded listed option transactions, which require the delivery of the securities listed under this prospectus. After our securities are qualified for quotation on the over the counter market, the selling shareholders may also transfer securities owned in other ways not involving market makers or established trading markets, including directly by gift, distribution, or other transfer without consideration, and upon any such transfer the transferee would have the same rights of sale as such selling shareholders under this prospectus.
In addition to the above, each of the selling shareholders will be affected by the applicable provisions of the Securities Exchange Act of 1934, including, without limitation, Regulation M, which may limit the timing of purchases and sales of any of the securities by the selling shareholders or any such other person. We have instructed our selling shareholders that they may not purchase any of our securities while they are selling shares under this registration statement.
Upon this registration statement being declared effective, the selling shareholders may offer and sell their shares from time to time until all of the shares registered are sold; however, this offering may not extend beyond two (2) years from the initial effective date of this registration statement.
32
There can be no assurances that the selling shareholders will sell any or all of the securities. In various states, the securities may not be sold unless these securities have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.
All of the foregoing may affect the marketability of our securities. Pursuant to oral promises we made to the selling shareholders, we will pay all the fees and expenses incident to the registration of the securities.
Should any substantial change occur regarding the status or other matters concerning the selling shareholders or us, we will file a post-effective amendment to this registration statement disclosing such matters.
OTC Markets Considerations
To be quoted on the OTC Markets, a market maker must file an application on our behalf in order to make a market for our common stock. We anticipate that after this registration statement is declared effective, market makers will enter “piggyback” quotes and our securities will thereafter trade on the OTC Markets.
The OTC Markets is separate and distinct from the NASDAQ stock market. NASDAQ has no business relationship with issuers of securities quoted on the OTC Markets. The SEC’s order handling rules, which apply to NASDAQ-listed securities, do not apply to securities quoted on the OTC Markets.
Although the NASDAQ stock market has rigorous listing standards to ensure the high quality of its issuers, and can delist issuers for not meeting those standards, the OTC Market has no listing standards. Rather, it is the market maker who chooses to quote a security on the system, files the application, and is obligated to comply with keeping information about the issuer in its files. FINRA cannot deny an application by a market maker to quote the stock of a company. The only requirement for inclusion in the bulletin board is that the issuer be current in its reporting requirements with the SEC.
Although we anticipate listing on the OTCQB will increase liquidity for our stock, investors may have greater difficulty in getting orders filled because it is anticipated that if our stock trades on a public market, it initially will trade on the OTCQB rather than on NASDAQ. Investors’ orders may be filled at a price much different than expected when an order is placed. Trading activity in general is not conducted as efficiently and effectively as with NASDAQ-listed securities.
Investors must contact a broker-dealer to trade OTC securities. Investors do not have direct access to the service. For OTC securities, there only has to be one market maker.
Because OTC stocks are usually not followed by analysts, there may be lower trading volume than for NASDAQ-listed securities.
There is no guarantee that our stock will ever be quoted on the OTCQB.
We are not aware of any pending or threatened legal proceedings in which we are involved.
33
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS
The board of directors elects our executive officers annually. A majority vote of the directors who are in office are required to fill vacancies. Each director shall be elected for three (3) years and until his or her successor is elected and qualified, or until his earlier resignation or removal. Our directors and executive officers are as follows:
NAME | AGE | POSITION | ||
Jeff Toghraie | 50 | Chief Executive Officer and Chairman | ||
Chris Go | 53 | Secretary | ||
Jeff Brown | 44 | Chief Operating Officer | ||
Donald Starace | 63 | President | ||
Nancy Hundt | 49 | Director |
Jeff Togharie – Chairman of the Board of Directors, Chief Executive Officer
Jeff Toghraie has been the Chairman of our board since 2015 and our Chief Executive Officer since 2016. Mr. Toghraie is currently the Managing Director of Intrepid Global Advisors, one of our principal shareholders. Mr. Toghraie joined Intrepid Global Advisors in 2010 and is a principal of that firm. During the past 5 years, Mr. Toghraie has been involved with various privately held development stage companies as a director and/or advisory positions.
Sunook Park – Chief Creative Officer
Sunook Park joined our company as Chief Creative Officer in 2015. Mr. Park has 20 years experience in full scale corporate and brand identity projects for social and business entities worldwide. Mr. Park has participated in corporate identity and branding projects for The Gillette Company, ARCO(am/pm Mini Mart), American Heart Association, Colgate Company, Tropical Safety Research, Hitch, IPIX, KIA Motors, Carsdirect.com, CDZON.com, Conexant and Nike.
Chris Go – Secretary
Christopher Go has served as our Corporate Secretary since 2015. From 2009-2012 Mr. Go was the VP of Operations for TEN Media, a funded food safety & traceability platform involving Walmart, Safeway, cal-Marine, Dutch Farms, USDA, FDA & Yucaipa Companies. From 1996-1998 Mr. Go was staff architect for WAT&G.
Donald Starace – President
Mr. Starace has forty years of dedicated service in the beauty industry. Mr. Starace started his career in some of New York’s most prestigious salons, followed by ten years at Nioxin Research Labs and subsequently Proctor & Gamble in Sales and Education. Mr. Starace owned and operated various businesses through his career including roles in starting the Bank of New Jersey, which currently holds 10 locations, and has assets over $865 million. He was one of the initial investors for the bank and very influential in raising capital. He also facilitated bringing Taiff ( Barzil ) professional appliances to the hair industry in the U.S. and Canada. Mr. Starace most recently was appointed as a member of the Board of Adjustments for the Borough of Fort Lee, New Jersey.
Nancy Hundt - Director
Nancy Hundt has served as a director of Reviv3 Procare Company since May of 2015. Ms. Hundt has a diverse background in the retail industry and has served as a representative of the American Board of Opticianery, an optical industry retail group. Ms. Hundt acts as a consultant as a retail sales expert and has served over the last five years as Chief Operating Officer of Academy Optical, Inc.
Family Relationships
There are no family relationships with the Company.
34
Legal Proceedings
We are not aware of any pending or threatened legal proceedings in which the aforementioned individuals are involved.
No officer, director, or persons nominated for such positions, promoter or significant employee has been involved in the last ten (10) years in any of the following:
● | Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; |
● | Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); |
● | Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; |
● | Being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; |
● | Having any government agency, administrative agency, or administrative court impose an administrative finding, order, decree, or sanction against them as a result of their involvement in any type of business, securities, or banking activity; |
● | Being the subject of a pending administrative proceeding related to their involvement in any type of business, securities, or banking activity; and/or |
● | Having any administrative proceeding been threatened against you related to their involvement in any type of business, securities, or banking activity. |
Corporate Governance
Our officers and directors, Jeff Toghraie, Sunook Park and Chris Go are not “independent” as the term is used in Item 7(d) (3) (iv) (B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a) (15) of the NASDAQ Marketplace Rules because they are employed by the company.
We do not have any standing audit, nominating and compensation committees of the board of directors, or committees performing similar functions. We do not currently have a Code of Ethics applicable to our principal executive, financial or accounting officer. All Board actions have been taken by Written Action rather than formal meetings.
35
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following tables set forth the ownership, as of the date of this prospectus, of our common stock by each person known by us to be the beneficial owner of more than five percent (5%) of our outstanding common stock, our directors, and our executive officers as a group. The persons named have sole voting and investment power with respect to such shares, except as otherwise noted. There are not any pending or anticipated arrangements that may cause a change in control.
The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a "beneficial owner" of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within sixty (60) days through the conversion or exercise of any convertible security, warrant, option or other right. More than one (1) person may be deemed to be a beneficial owner of the same securities. The percentage of beneficial ownership by any person as of a particular date is calculated by dividing the number of shares beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting or investment power within sixty (60) days, by the sum of the number of shares outstanding as of such date. Consequently, the denominator used for calculating such percentage may be different for each beneficial owner. Except as otherwise indicated below and under applicable community property laws, we believe that the beneficial owners of our common stock listed below have sole voting and investment power with respect to the shares shown.
Title of Class |
Name/Position |
Beneficial Ownership |
Percentage Of Class |
|||||||
Executive Beneficial Owners | ||||||||||
Common | Jeff Toghraie/Director CEO (1) | 9,334,000 | 23.04 | % | ||||||
Common | Park Sunook/Chief Creative Director | 51,000 | 0.13 | % | ||||||
Common | Chris Go/Secretary (2) | 1,025,709 | 2.53 | % | ||||||
Common | Nancy Hundt (3) | 2,600,000 | 6.42 | % | ||||||
All Officers and Directors | 13,010,709 | 32.12 | % | |||||||
Non-Executive Beneficial Owners | ||||||||||
Common | Axon Capital Management, Inc. (4) | 3,600,000 | 8.89 | % | ||||||
Common | Charter Capital Partners (5) | 3,600,000 | 8.89 | % | ||||||
Common | Shircoo, Inc. (6) | 13,010,000 | 32.12 | % | ||||||
All Non-Executive Beneficial Owners | 13,010 | 49.90 | % | |||||||
All Beneficial Owners | 33,219,709 | 82.02 | % |
(1) | Jeff Toghraie, our sole Director and CEO, is the sole beneficiary of Intrepid Global Advisors, which holds 9,334,000 shares of common capital stock of the Company. |
(2) | Chris Go, our Chief Creative Director, is the Managing Partner of Titan HG, LLC, which holds 1,025,709 shares of common capital stock of the Company. |
(3) | Nancy Hundt holds the shares personally, residing at 31569 Lindero Canyon Rd., #3, Westlake Village, CA 91361 |
(4) | Sam Toghraie who is the brother of Jeff Toghraie, our sole Director and CEO, is a partner at Axon Capital Management, Inc. Axon Capital Management, Inc. has offices at 5490 Whister Ct., Chino Hills, CA 91709 |
(5) | Charter Capital Partners is managed by its Managing Partner, Parvan Riazi. Charter Capital Partners maintains offices at 1964 Laurel Wood Ct. Thousand Oaks CA 91362 |
(6) | Shircoo, Inc. is managed by Max Toghraie, its Managing Partner who is the brother of our sole Director and CEO, Jeff Toghraie. Shircoo, Inc. maintains offices at 2350 E. Allview Terrace, Los Angeles CA 90068 |
36
The following description is a summary of the material terms of the provisions of our Articles of Incorporation and Bylaws. Our Articles of Incorporation and Bylaws have been filed as exhibits to the registration statement of which this prospectus is a part.
Common Stock
We are authorized to issue 100,000,000 shares of common stock, $0.0001 par value per share. As of the date of this prospectus there are 40,505,047 shares of our common stock issued and outstanding held by 75 stockholders of record. We are authorized to issue 20,000,000 shares of blank check preferred stock of which there are no shares are outstanding.
Each share of our common stock entitles the holder to one (1) vote, either in person or by proxy, at meetings of shareholders. The shareholders are not permitted to vote their shares cumulatively. Accordingly, the holders of more than fifty percent (50%) of the total voting rights on matters presented to our common stockholders can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any such directors. The vote of the holders of a majority of the holders entitled to vote on matters submitted to our common stockholders is sufficient to authorize, affirm, ratify, or consent to such act or action, except as otherwise provided by law.
To date, we have paid no cash dividends on our shares of common stock. Any future disposition of dividends will be at the discretion of our Board of directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors. We have no present plans for future cash or stock dividends. We intend to retain future earnings, if any, to provide funds for operation of our business.
Holders of our common stock have no preemptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or windup, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. There are not any provisions in our Articles of Incorporation or our Bylaws that would prevent or delay change in our control.
All shares of common stock outstanding are validly issued, fully paid, and non-assessable.
Preferred Shares
We are authorized to issue 20,000,000 shares of preferred stock with a par value of $0.0001 per share of which no shares are outstanding or designated otherwise. Our Board of Directors may designate the authorized but unissued shares of the Preferred Stock with such rights and privileges as the Board of Directors may determine without a vote of our stockholders. As such, our Board of Directors may issue 20,000,000 preferred shares and designate the conversion, voting and other rights and preferences without notice to our shareholders and without shareholder approval.
Delaware Anti-Takeover Laws
As a Delaware corporation, we are subject to certain anti-takeover provisions that apply to public corporations under Delaware law. Pursuant to Section 607.0901 of the Delaware Business Corporation Act, or the Delaware Act, a publicly held Delaware corporation may not engage in a broad range of business combinations or other extraordinary corporate transactions with an interested shareholder without the approval of the holders of two-thirds of the voting shares of the corporation (excluding shares held by the interested shareholder), unless:
● | the transaction is approved by a majority of disinterested directors before the shareholder becomes an interested shareholder; |
● | the interested shareholder has owned at least eighty percent (80%) of the corporation’s outstanding voting shares for at least five years preceding the announcement date of any such business combination; |
● | the interested shareholder is the beneficial owner of at least ninety percent (90%) of the outstanding voting shares of the corporation, exclusive of shares acquired directly from the corporation in a transaction not approved by a majority of the disinterested directors; or |
● | the consideration paid to the holders of the corporation’s voting stock is at least equal to certain fair price criteria. |
An interested shareholder is defined as a person who, together with affiliates and associates, beneficially owns more than ten percent (10%) of a corporation’s outstanding voting shares. We have not made an election in our amended Articles of Incorporation to opt out of Section 607.0901.
In addition, we are subject to Section 607.0902 of the Delaware Act which prohibits the voting of shares in a publicly held Delaware corporation that are acquired in a control share acquisition unless (i) our board of directors approved such acquisition prior to its consummation or (ii) after such acquisition, in lieu of prior approval by our board of directors, the holders of a majority of the corporation’s voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting of voting rights as to the shares acquired in the control share acquisition. A control share acquisition is defined as an acquisition that immediately thereafter entitles the acquiring party to twenty percent (20%) or more of the total voting power in an election of directors.
37
The financial statements as of May 31, 2017 and 2016 and for each of the two years in the period ended May 31, 2017, included in this prospectus have been audited by Salberg & Company, P.A., our independent registered public accounting firm, to the extent and for the periods set forth in their report and are incorporated herein in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.
The legality of the shares offered under this registration statement is being passed upon by Eilers Law Group, P.A.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES LIABILITIES
Our Bylaws, subject to the provisions of Delaware Law, contain provisions which allow the corporation to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes, and other financial information included in this prospectus.
Our Management's Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. Forward-looking statements are often identified by words like: “believe”, “expect”, “estimate”, “anticipate”, “intend”, “project” and similar expressions, or words that, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this prospectus. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. These risks and uncertainties include international, national, and local general economic and market conditions; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; change in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; the risk of foreign currency exchange rate; and other risks that might be detailed from time to time in our filing with the Securities and Exchange Commission. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in “Risk Factors”.
Although the forward-looking statements in this Registration Statement reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.
Our financial statements are stated in United States Dollars (USD or US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. All references to “common stock” refer to the common shares in our capital stock.
38
Overview
REVIV3 PROCARE COMPANY is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products under various trademarks and brands, and has adopted and used the trademarks products for distribution throughout the United States, Canada, Europe and Asia pursuant to the terms of 11 exclusive distribution agreements with various parties throughout our targeted market. All of our products use tested and FDA approved, all-natural products. Our manufacturing operations are outsourced and fulfilled by through our co-packers and manufacturing partners. Currently, we produce 7 products with 13 separate sku’s and look to expand our product lines significantly over the next 12 months.
Since our inception, we have engaged in significant operational activities as described in "Business," above.
We are an "emerging growth company" ("EGC") that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act ("the JOBS Act"), that eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the U.S. Securities and Exchange Commission's (SEC's) reporting and disclosure rules (See "Emerging Growth Companies" section above). We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the Jobs Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
As of May 31, 2017, we had $444,507 cash on hand for our operational needs. Currently, our operating expenses are approximately $26,000.00 per month or $312,000 annually. We will require approximately $20,800 per month or $250,000 over the next twelve (12) months to meet our existing operational costs, which consist of rent, advertising, salaries and other general, administrative expenses and to comply with the costs of being an SEC reporting company. If we fail to generate sufficient revenues to meet our monthly operating, post registration, costs of $35,000, we will not have available cash for our operating needs after approximately less than one month.
Results of Operations
Our results of operations are summarized below. To date, we have not generated revenue from business operations.
Year Ended
May 31, 2017 |
Year Ended
May 31, 2016 |
|||||||
Revenues | $ | 582,005 | $ | 475,756 | ||||
Cost of Sales | $ | 281,579 | $ | 278,347 | ||||
Total operating expenses | $ | 838,632 | $ | 912,089 | ||||
Loss from operations | $ | (538,206 | ) | $ | (714,680 | ) | ||
Net loss | $ | (538,777 | ) | $ | (773,658 | ) |
For the year ended May 31, 2017, revenues increased by approximately $106,000, or 22%, as compared to the year ended May 31, 2016, which is primarily due to increase marketing efforts and direct to consumer sales and salon sales.
Cost of sales includes the cost of product and shipping fee. For the year ended May 31, 2017, cost of sales increased by 3,232, or 1.2%, as compared to the year ended May 31, 2016.
For the year ended May 31, 2017, gross profit amounted to $300,426 as compared to $197,409, an increase of $103,017, or 52.2%. For the years ended May 31, 2017 and 2016, gross profit margins amounted to 51.6% and 41.5%, respectively. The increase in gross profit margins in 2017 and compared to 2016 was attributable to a decrease in overall product costs related to cost efficiencies obtained as a result of increases in quantities purchased.
For the year ended May 31, 2017 and 2016, we incurred operating expenses of $838,632 and $912,089, respectively, and a net loss of $(538,777) and $(773,658), respectively. The operating expenses are costs related to marketing and selling expenses, compensation and related taxes, professional and consulting fees, and general and administrative costs. Operating expenses decreased by approximately $73,000 or 8% primarily due to a decreased stock based consulting expenses related to business advisory service agreements and decreased in compensation due to decrease in full time employees offset by increase in marketing and selling expenses due to increase marketing efforts and awareness of our products, increase legal expenses related to applications of our trademarks and increase in general administrative expenses primarily attributable to increase rent and travel expenses.
Other expense decrease by approximately $58,000 or 99% primarily due to decrease interest expense as a result of the payment of the note payable in December 2015.
39
Liquidity and Capital Resources
The following table provides detailed information about our net cash flows presented in this Report.
For the
year Ended May 31, 2017 |
For the
year Ended May 31, 2016 |
|||||||
Cash Flows | ||||||||
Net cash used in operating activities | $ | (369,965 | ) | $ | (321,733 | ) | ||
Net cash used in investing activities | (5,458 | ) | (3,673 | ) | ||||
Net cash provided by financing activities | 422,600 | 692,459 | ||||||
Net change in cash | $ | 47,177 | $ | 367,053 |
We are an emerging growth company and currently engaged in our initial product sales and development. We have an accumulated deficit and have incurred operating losses since our inception and expect losses to continue during fiscal year 2018. Our auditor has indicated in their Report that these conditions raise substantial doubt about our ability to continue as a going concern.
Operating Activities
Cash used in operating activities for the year end May 31, 2017 consisted of net loss as well as the effect of changes in operating assets and liabilities as well as adjustments to reconcile net to loss to net cash used in operating activities. Cash used in operating activities of $(369,965) consisted of a net loss of $(538,777). The net loss was partially offset by reconciliation of depreciation of $1,386,bad debt of $810, stock based compensation $131,342, inventory obsolescence of $7,230 and net changes in operating assets and liabilities of $28,044 primarily from an decrease in inventory, advances to suppliers and increase in accounts payable and accrued expenses.
Cash used in operating activities for the year end May 31, 2016 consisted of net loss as well as the effect of changes in operating assets and liabilities as well as adjustments to reconcile net to loss to net cash used in operating activities. Cash used in operating activities of $(321,733) consisted of a net loss of $(773,658). The net loss was partially offset by reconciliation of depreciation of $490, inventory obsolescence of $11,993, stock based compensation of $470,674, amortization of debt discount of $53,151, offset by the net changes in operating assets and liabilities of $86,865 primarily due to increase in inventory, advance to suppliers, and decrease accounts payable and accrued expenses..
Investing Activities
For the year ended May 31, 2017 and 2016, we derived cash flow from investing activities of $(5,458) and $(3,673), respectively, consisting of purchases of equipment and property.
Financing Activities
For the year ended May 31, 2017 we raised $422,501 from the sale of our common shares to investors for cash consideration. We also had capital contribution of $99 from a related party for a total of $422,600.
For the year ended May 31, 2016 we raised $792,459 from the sale of our common shares to investors for cash consideration. This was offset by payment of $100,000 for a note payable.
We currently have no external sources of liquidity, such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.
40
We are dependent on our product sales to fund our operations, and may require the sale of additional common stock to maintain operations. Our officers and directors have made no written commitments with respect to providing a source of liquidity in the form of cash advances, loans and/or financial guarantees.
If we are unable to raise the funds required to fund our operations, we will seek alternative financing through other means, such as borrowings from institutions or private individuals. There can be no assurance that we will be able to raise the capital we need for our operations from the sale of our securities. We have not located any sources for these funds and may not be able to do so in the future. We expect that we will seek additional financing in the future. However, we may not be able to obtain additional capital or generate sufficient revenues to fund our operations. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to cease operations. If we fail to raise funds, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.
Seasonality
We do not believe our business is subject to substantial seasonal fluctuations. We may experience lower sales in difficult economic scenarios but we do not foresee the seasonality of our products to be a significant factor. Seasonality trends could however have a material impact on our financial condition and results of operations in the future but we are not currently aware of the total impact that could result.
Inflation
Our business and operating results are not affected in any material way by inflation.
We currently lease just over 7,000 square feet at our facility in El Monte, California for approximately $7,000 per month.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
In August 2016, the Company received loan proceeds of $675,000 from a related party. The Company may prepay the loan in full during the first 60 days without incurring any interest on the balance. However, interest-free period shall cease on October 1, 2016 at which time the note accrues interest at a rate of 8% per annum. The Company paid off this loan in September 2016 and the Company did not incur any interest charges. The related party is an affiliated company managed by the brother of the Company’s Chief Executive Officer.
During the year ended May 31, 2016, the Company sold an aggregate of 4,400,000 shares of its common stock to an affiliated company at prices ranging from $0.03 to $0.07 per common share for proceeds of approximately $172,000. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
During the year ended May 31, 2016, the Company sold an aggregate of 3,430,000 shares of its common stock to an affiliated company at prices ranging from $0.03 to $0.07 per common share for proceeds of approximately $120,100. The affiliated company is managed by the Company’s Chief Executive Officer.
During the year ended May 31, 2016, the Company issued 5,000,000 shares of the Company’s common stock to an affiliated company pursuant to a consulting agreement related to marketing and business advisory services. The term of the consulting agreement was for 12 months. The Company valued these common shares at the fair value of $150,000 based on the sale of common stock in the recent private placement at $0.03 per common share. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
41
During the year ended May 31, 2016, the Company issued 3,200,000 shares of the Company’s common stock to an affiliated company pursuant to a consulting agreement related to marketing and business advisory services. The term of the consulting agreement was for 12 months. The Company valued these common shares at the fair value of $96,000 based on the sale of common stock in the recent private placement at $0.03 per common share. The affiliated company is managed by the Company’s Chief Executive Officer.
During the year ended May 31, 2017, the Company sold 1,010,000 shares of its common stock to an affiliated company at $0.25 per common share for proceeds of approximately $253,000. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
Corporate Governance and Director Independence
Our Board of Directors has not established Audit, Compensation, and Nominating or Governance Committees as standing committees. The Board does not have an executive committee or any committees performing a similar function. We are not currently listed on a national securities exchange or in an inter-dealer quotation system that has requirements that a majority of the board of directors be independent. Our Directors have determined that they are not “independent” under the definition set forth in the listing standards of the NASDAQ Stock Market, which is the definition that the Board has chosen to use for the purposes of the determining independence, as the OTC Markets does not provide such a definition. Therefore, our directors are not independent.
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Market Information
There is no established public trading market for our securities and a regular trading market may not develop, or if developed, may not be sustained. A shareholder in all likelihood, therefore, will not be able to resell his or her securities should he or she desire to do so when eligible for public resale. Furthermore, it is unlikely that a lending institution will accept our securities as pledged collateral for loans unless a regular trading market develops.
Penny Stock Considerations
Our shares will be "penny stocks", as that term is generally defined in the Securities Exchange Act of 1934 to mean equity securities with a price of less than $5.00 per share. Thus, our shares will be subject to rules that impose sales practice and disclosure requirements on broker-dealers who engage in certain transactions involving a penny stock.
Under the penny stock regulations, a broker-dealer selling a penny stock to anyone other than an established customer must make a special suitability determination regarding the purchaser and must receive the purchaser's written consent to the transaction prior to the sale, unless the broker-dealer is otherwise exempt.
In addition, under the penny stock regulations, the broker-dealer is required to:
● | deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the Securities and Exchange Commission relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt; |
● | disclose commissions payable to the broker-dealer and our registered representatives and current bid and offer quotations for the securities; |
● | send monthly statements disclosing recent price information pertaining to the penny stock held in a customer's account, the account's value, and information regarding the limited market in penny stocks; and |
● | make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction, prior to conducting any penny stock transaction in the customer's account. |
42
Because of these regulations, broker-dealers may encounter difficulties in their attempt to sell shares of our common stock, which may affect the ability of selling shareholders or other holders to sell their shares in the secondary market, and have the effect of reducing the level of trading activity in the secondary market. These additional sales practice and disclosure requirements could impede the sale of our securities, if our securities become publicly traded. In addition, the liquidity for our securities may be decreased, with a corresponding decrease in the price of our securities. Our shares in all probability will be subject to such penny stock rules and our shareholders will, in all likelihood, find it difficult to sell their securities.
OTC Markets Qualification for Quotation
To have our shares of common stock on the OTC Market, a market maker must file an application on our behalf in order to make a market for our common stock. We have engaged in preliminary discussions with a FINRA Market Maker to file our application on Form 211 with FINRA, but as of the date of this Prospectus, no filing has been made. Based upon our counsel's prior experience, we anticipate that after this registration statement is declared effective, it will take approximately 2 - 8 weeks for FINRA to issue a trading symbol and allow sales of our common stock under Rule 144.
Sales of Our Common Stock Under Rule 144
We presently have 40,505,047 common shares outstanding. Of these shares 7,285,338 common shares are held by non-affiliates and 33,219,709 common shares are held by affiliates, which Rule 144 of the Securities Act of 1933, as amended, defines as restricted securities. None of our outstanding shares are eligible for resale under Rule 144.
We are registering 3,590,532, common shares held by non-affiliates. We are not registering shares held by affiliates. The remaining
non-affiliate shares as well as all of the remaining affiliates’ shares will still be subject to the resale restrictions
of Rule 144. In general, persons holding restricted securities, including affiliates, must hold their shares for a period of at
least six (6) months, may not sell more than one (1) percent of the total issued and outstanding shares in any 90-day period,
and must resell the shares in an unsolicited brokerage transaction at the market price. The availability for sale of substantial
amounts of common stock under Rule 144 could reduce prevailing market prices for our securities.
Holders
As of the date of this registration statement, we had 75 shareholders of record of our common stock.
Dividends
We have not declared any cash dividends on our common stock since our inception and do not anticipate paying such dividends in the foreseeable future. We plan to retain any future earnings for use in our business. Any decisions as to future payments of dividends will depend on our earnings and financial position and such other facts, as the board of directors deems relevant.
Transfer Agent
Our transfer agent is West Coast Stock Transfer located at 721 N. Vulcan Ave. Ste. 205 Encinitas, CA 92024. Their telephone number is (619) 664-4780 and their website is located at http://www.westcoaststocktransfer.com.
Reports to Shareholders
As a result of this offering and assuming the registration statement is declared effective before January 15, 2018, as required under Section 15(d) of the Securities Exchange Act of 1934, we will file periodic reports with the Securities and Exchange Commission through January 15, 2018, including a Form 10-Q for the six months ended November 31, 2017, assuming this registration statement is declared effective before that date. At or prior to January 15, 2017, we intend voluntarily to file a registration statement on Form 8-A which will subject us to all of the reporting requirements of the 1934 Act. This will require us to file quarterly and annual reports with the SEC and will also subject us to the proxy rules of the SEC. In addition, our officers, directors and ten percent (10%) stockholders will be required to submit reports to the SEC on their stock ownership and stock trading activity. We are not required under Section 12(g) or otherwise to become a mandatory 1934 Act filer unless we have more than 500 shareholders and total assets of more than $10 million on May 31, 2018. If we do not file a registration statement on Form 8-A at or prior to May 31, 2018, we will continue as a voluntary reporting company and will not be subject to the proxy statement or other information requirements of the 1934 Act, our securities can no longer be quoted on the OTC Quotation Board, and our officers, directors and ten percent (10%) stockholders will not be required to submit reports to the SEC on their stock ownership and stock trading activity. We will deliver an annual report to our security holders that will include audited financial statements regardless of whether we are obligated to do so.
43
Where You Can Find Additional Information
We have filed with the Securities and Exchange Commission a registration statement on Form S-1. For further information about us and the shares of common stock to be sold in the offering, please refer to the registration statement and the exhibits and schedules thereto. The registration statement and exhibits and any materials we file with the Commission may be read and copied, at the SEC's Public Reference Room at 100 F St., N.E., Washington, D.C. 20549, on official business days during the hours of 10 a.m. to 3 p.m. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Commission and state the address of that site ( http://www.sec.gov ). Our registration statement and other information we file with the SEC is available at the web site maintained by the SEC at http://www.sec.gov .
Summary Compensation Table
The table below summarizes all compensation awarded to, earned by, or paid to our Principal Executive Officer, our two most highly compensated executive officers who occupied such position at the end of our latest fiscal year and up to two additional executive officers who would have been included in the table below except for the fact that they were not executive officers at the end of our latest fiscal year, by us, or by any third party where the purpose of a transaction was to furnish compensation, for all services rendered in all capacities to us for the periods ended May 31, 2017, May 31, 2016 and May 31, 2015.
Name and Principal Position |
Year
Ended May 31 |
Salary | Bonus | Stock Awards(1) |
Option
Awards |
Non-Equity
Incentive Plan Compensation Earnings |
Non-
Qualified Deferred Compensation Earnings |
All Other
Compensation |
Total | |||||||||
Jeff Toghraie, Chief Executive Officer & Director(2) | 2017 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- | |||||||||
2016 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- | ||||||||||
2015 | -0- | -0- | 4,932,000 | -0- | -0- | -0- | -0- | $345,240 | ||||||||||
Sunook Park, Chief Creative Officer | 2017 | -0- | -0- | 51,000 | -0- | -0- | -0- | -0- | $12,750 | |||||||||
2016 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- | ||||||||||
2015 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- | ||||||||||
Chris Go, Secretary | 2017 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- | |||||||||
2016 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- | ||||||||||
2015 | -0- | -0- | -0- | -0- | -0- | -0- | -0- | -0- |
(1) | Stock Award valuations are based upon the offering of common stock most recently sold at the time of the issuance. Specifically, issuances in 2015 were based upon $0.07 per share while issuances in 2017 were based upon $0.25 per share. |
(2) | Jeff Toghraie is the sole owner of Intrepid Global Advisors that provided Advisory services for the Company in 2015 in exchange for shares. |
44
Outstanding Equity Awards at the End of the Fiscal Year
We do not have and have never had any equity compensation plans and therefore no equity awards are outstanding as of the date of this registration statement.
Directors Compensation
Our directors do not receive any other compensation for serving on the board of directors.
Bonuses and Deferred Compensation
Per our current agreements with our officers and directors, we may pay applicable bonuses in addition as are awarded by the Board of Directors from time to time based on performance, which may either be paid in stock or cash at the discretion of the Board.
Options and Stock Appreciation Rights
We do not currently have a stock option or other equity incentive plan. We may adopt one or more such programs in the future.
Payment of Post-Termination Compensation
We do not have change-in-control agreements with any of our directors or executive officers, and we are not obligated to pay severance or other enhanced benefits to executive officers upon termination of their employment.
Involvement in Certain Legal Proceedings
There have been no events under any bankruptcy act, no criminal proceedings, no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any of our directors, executive officers, promoters, or control persons during the past ten (10) years.
Board of Directors
All directors hold office until the expiration of their term and until their successors have been duly elected and qualified. Officers are elected by and serve at the discretion of the board of directors.
45
Our directors are reimbursed for expenses incurred by them in connection with attending board meetings, but they do not receive any other compensation for serving on the board of directors.
Name and
Principal Position |
Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | Number of Shares of Units of Stock That Have Not Vested (#) |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
|||||||||||||||||||||||||||
Jeff Toghraie | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
Nancy Hundt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Employment Agreements with Management
Our board of directors determines the compensation paid to our executive officers based upon the years of service to us, whether services are provided on a full-time basis and the experience and level of skill required.
We may award our officers and directors shares of common stock as non-cash compensation as determined by the board of directors from time to time. The board will base its decision to grant common stock as compensation on the level of skill required to perform the services rendered and time committed to providing services to us.
At no time during the last fiscal year with respect to any person listed in the Table above was there:
● | Any outstanding option or other equity-based award re-priced or otherwise materially modified (such as by extension of exercise periods, the change of vesting or forfeiture conditions, the change or elimination of applicable performance criteria, or the change of the bases upon which returns are determined); |
● | Any waiver or modification of any specified performance target, goal or condition to payout with respect to any amount included in non-stock incentive plan compensation or payouts; |
● | Any option or equity grant; |
● | Any non-equity incentive plan award made to a named executive officer; |
● | Any nonqualified deferred compensation plans including nonqualified defined contribution plans; or |
● | Any payment for any item to be included under in the Summary Compensation Table. |
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
46
FINANCIAL STATEMENTS
May 31, 2017 and 2016
F- 1
REVIV3 PROCARE COMPANY
INDEX TO FINANCIAL STATEMENTS
May 31, 2017 and 2016
CONTENTS
F- 2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of:
Reviv3 Procare Company.
We have audited the accompanying balance sheets of Reviv3 Procare Company as of May 31, 2017 and 2016 and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the two years in the period ended May 31, 2017. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Reviv3 Procare Company as of May 31, 2017 and 2016 and the results of its operations and its cash flows for each of the two years in the period ended May 31, 2017 in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has a net loss and cash used in operations of $538,777 and $369,965 in 2017 and has an accumulated deficit of $4,145,628 at May 31, 2017. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s Plan in regards to these matters is also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ Salberg & Company, P.A.
SALBERG & COMPANY, P.A.
Boca Raton, Florida
October 6, 2017
2295 NW Corporate Blvd., Suite 240 • Boca Raton, FL 33431-7328
Phone: (561) 995-8270 • Toll Free: (866) CPA-8500 • Fax: (561) 995-1920
www.salbergco.com • info@salbergco.com
Member National Association of Certified Valuation Analysts • Registered with the PCAOB
Member CPAConnect with Affiliated Offices Worldwide • Member AICPA Center for Audit Quality
F- 3
BALANCE SHEETS
May 31, | ||||||||
2017 | 2016 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash | $ | 416,873 | $ | 369,696 | ||||
Accounts receivable, net | 32,703 | 29,072 | ||||||
Inventory | 129,794 | 148,719 | ||||||
Advance to suppliers | 16,135 | 30,348 | ||||||
Prepaid expenses and other current assets | 18,089 | 106,811 | ||||||
Deposit | - | 9,455 | ||||||
Total Current Assets | 613,594 | 694,101 | ||||||
OTHER ASSETS: | ||||||||
Property and equipment, net | 7,255 | 3,183 | ||||||
Deposits | 14,849 | - | ||||||
Total Other Assets | 22,104 | 3,183 | ||||||
TOTAL ASSETS | $ | 635,698 | $ | 697,284 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable and accrued expenses | $ | 62,968 | $ | 27,539 | ||||
Customer deposits | 20,246 | 37,704 | ||||||
Total Current Liabilities | 83,214 | 65,243 | ||||||
Total Liabilities | 83,214 | 65,243 | ||||||
Commitments and contingencies (see Note 7) | ||||||||
STOCKHOLDERS’ EQUITY: | ||||||||
Preferred stock, $0.0001 par value; 20,000,000 shares authorized; none issued and outstanding | - | - | ||||||
Common stock, $0.0001 par value: 100,000,000 shares authorized; 39,679,047 and 38,150,981 shares issued and outstanding as of May 31, 2017 and 2016 | 3,968 | 3,815 | ||||||
Additional paid-in capital | 4,694,144 | 4,235,077 | ||||||
Accumulated deficit | (4,145,628 | ) | (3,606,851 | ) | ||||
Total Stockholders’ Equity | 552,484 | 632,041 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 635,698 | $ | 697,284 |
See accompanying notes to financial statements.
F- 4
STATEMENTS OF OPERATIONS
For the Years Ended | ||||||||
May 31,
2017 |
May 31,
2016 |
|||||||
Sales | $ | 582,005 | $ | 475,756 | ||||
Cost of sales | 281,579 | 278,347 | ||||||
Gross profit | 300,426 | 197,409 | ||||||
OPERATING EXPENSES: | ||||||||
Marketing and selling expenses | 103,602 | 70,484 | ||||||
Compensation and related taxes | 87,132 | 125,643 | ||||||
Professional and consulting expenses | 403,883 | 531,558 | ||||||
General and administrative | 244,015 | 184,404 | ||||||
Total Operating Expenses | 838,632 | 912,089 | ||||||
LOSS FROM OPERATIONS | (538,206 | ) | (714,680 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 5 | - | ||||||
Gain on settlement of debt | - | 6,551 | ||||||
Interest expense | (576 | ) | (65,529 | ) | ||||
Other Income (Expense), Net | (571 | ) | (58,978 | ) | ||||
LOSS BEFORE PROVISION FOR INCOME TAXES | (538,777 | ) | (773,658 | ) | ||||
Provision for income taxes | - | - | ||||||
NET LOSS | $ | (538,777 | ) | $ | (773,658 | ) | ||
NET LOSS PER COMMON SHARE - Basic and diluted | $ | (0.01 | ) | $ | (0.03 | ) | ||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||||||
Basic and diluted | 38,402,291 | 28,399,900 |
See accompanying notes to financial statements.
F- 5
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE YEARS ENDED MAY 31, 2017 and 2016
Additional | Total | |||||||||||||||||||||||||||
Preferred Stock | Common Stock | Paid-in | Accumulated | Stockholders’ | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
Balance, May 31, 2015 | - | $ | - | 7,446,148 | $ | 745 | $ | 2,865,721 | $ | (2,833,193 | ) | $ | 33,273 | |||||||||||||||
Issuance of common stock for cash | - | - | 11,455,333 | 1,145 | 791,314 | - | 792,459 | |||||||||||||||||||||
Issuance of common stock for services | - | - | 19,249,500 | 1,925 | 575,560 | - | 577,485 | |||||||||||||||||||||
Stock warrants issued for settlement of debt | - | - | - | - | 2,482 | - | 2,482 | |||||||||||||||||||||
Net Loss | - | - | - | - | - | (773,658 | ) | (773,658 | ) | |||||||||||||||||||
Balance, May 31, 2016 | - | - | 38,150,981 | 3,815 | 4,235,077 | (3,606,851 | ) | 632,041 | ||||||||||||||||||||
Issuance of common stock for cash | - | - | 1,419,066 | 142 | 422,359 | - | 422,501 | |||||||||||||||||||||
Issuance of common stock for services | - | - | 109,000 | 11 | 36,609 | - | 36,620 | |||||||||||||||||||||
Capital contribution | - | - | - | - | 99 | - | 99 | |||||||||||||||||||||
Net Loss | - | - | - | - | - | (538,777 | ) | (538,777 | ) | |||||||||||||||||||
Balance, May 31, 2017 | - | $ | - | 39,679,047 | $ | 3,968 | $ | 4,694,144 | $ | (4,145,628 | ) | $ | 552,484 |
See accompanying notes to financial statements.
F- 6
STATEMENTS OF CASH FLOWS
For the Years Ended | ||||||||
May 31,
2017 |
May 31,
2016 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (538,777 | ) | $ | (773,658 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 1,386 | 490 | ||||||
Bad debts | 810 | - | ||||||
Inventory obsolescence | 7,230 | 11,993 | ||||||
Stock based compensation | 131,342 | 470,674 | ||||||
Amortization of debt discount | - | 53,151 | ||||||
Gain on debt settlement | - | (6,551 | ) | |||||
Change in operating assets and liabilities: | ||||||||
Accounts receivable | (4,441 | ) | 8,302 | |||||
Inventory | 11,695 | (62,264 | ) | |||||
Advance to suppliers | 14,213 | (30,348 | ) | |||||
Prepaid expenses and other current assets | (6,000 | ) | - | |||||
Deposits | (5,394 | ) | - | |||||
Accounts payable and accrued expenses | 35,429 | (9,722 | ) | |||||
Customer deposits | (17,458 | ) | 16,200 | |||||
NET CASH USED IN OPERATING ACTIVITIES | (369,965 | ) | (321,733 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of property and equipment | (5,458 | ) | (3,673 | ) | ||||
NET CASH USED IN INVESTING ACTIVITIES | (5,458 | ) | (3,673 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Issuance of common stock for cash | 422,501 | 792,459 | ||||||
Note payable proceeds from related party | 675,000 | - | ||||||
Repayment of note payable to related party | (675,000 | ) | - | |||||
Repayment of note payable | - | (100,000 | ) | |||||
Capital contribution | 99 | - | ||||||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 422,600 | 692,459 | ||||||
NET INCREASE IN CASH | 47,177 | 367,053 | ||||||
CASH - Beginning of year | 369,696 | 2,643 | ||||||
CASH - End of year | $ | 416,873 | $ | 369,696 | ||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
Cash paid during the period for: | ||||||||
Interest | $ | - | $ | 9,000 | ||||
Income taxes | $ | - | $ | - | ||||
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
Issuance of common stock for prepaid services | $ | 12,089 | $ | 106,811 |
See accompanying notes to financial statements.
F- 7
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 1 – Organization
Reviv3 Procare Company (the “Company”) was incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC which was organized on July 31, 2013. The Company is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products throughout the United States, Canada, Europe and Asia.
On September 14, 2015, the Board of Directors of the Company approved a reverse stock split of the Company’s Common Stock at a ratio of 1-for-4 (the “Reverse Stock Split”) including shares issuable upon conversion of the Company’s outstanding convertible securities. All share and per share values of the Company’s common stock for all periods presented in the accompanying financial statements are retroactively restated for the effect of the Reverse Stock Split in accordance with Staff Accounting Bulletin 4C.
Note 2 – Summary of Significant Accounting Policies
Going Concern
As reflected in the accompanying financial statements, the Company has a net loss and net cash used in operations of $538,777 and $369,965, respectively, for the year ended May 31, 2017. Additionally the Company has an accumulated deficit of $4,145,628 at May 31, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. The ability of the Company to continue as a going concern is dependent on the Company’s ability to implement its business plan, raise capital, and generate sufficient revenue; however, the Company’s cash position may not be sufficient to support its daily operations. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company is unable to continue as a going concern.
Use of estimates
The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, and the fair value of non-cash common stock issuances.
Cash and cash equivalents
The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.
Accounts receivable and allowance for doubtful accounts
The Company has a policy of providing on allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of May 31, 2017 and 2016, the Company had recorded $810 and $0 in the allowance for doubtful accounts, respectively. The Company recorded bad debt expense of $810 and $0 during the years ended May 31, 2017 and 2016, respectively.
Prepaid expenses and other current assets
Prepaid expenses and other current assets of $18,089 and $106,811 at May 31, 2017 and 2016, respectively, consist primarily of costs paid for future services which will occur within a year. Prepaid expenses primarily included prepayments in common stock for consulting services which are being amortized over the terms of their respective agreements.
F- 8
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 2 – Significant and Critical Accounting Policies and Practices (continued)
Advances to suppliers
Advances to a supplier represents the cash paid in advance for installment payments for the purchase of inventory. The advances to a supplier are interest free and unsecured. As of May 31, 2017 and 2016, advances to the Company’s major supplier amounted $16,135 and $30,348, respectively. Upon shipment of the purchase inventory, the Company reclassifies such advances to supplier into inventory.
Inventory
The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations.
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.
Revenue recognition
The Company follows paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company will recognize revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.
Consideration paid to promote and sell the Company’s products to customers is typically recorded as a reduction in revenues in accordance with Accounting Standard Codification (“ASC”) ASC 605-50-45-2, Revenue Recognition—Customer Payments and Incentives.
Cost of Sales
The primary components of cost of sales include the cost of the product and shipping fees.
Shipping and Handling Costs
The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB Accounting Standards Codification. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $41,834 and $37,962 for the years ended May 31, 2017 and 2016, respectively.
Marketing, selling and advertising
Marketing, selling and advertising costs are expensed as incurred.
Customer Deposits
Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.
F- 9
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 2 – Significant and Critical Accounting Policies and Practices (continued)
Fair value measurements and fair value of financial instruments
The Company adopted Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.
These inputs are prioritized below:
Level 1: | Observable inputs such as quoted market prices in active markets for identical assets or liabilities |
Level 2: | Observable market-based inputs or unobservable inputs that are corroborated by market data |
Level 3: | Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. |
The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.
Income Taxes
The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.
The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.
The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.
F- 10
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 2 – Significant and Critical Accounting Policies and Practices (continued)
Impairment of long-lived assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not record any impairment losses during the years ended May 31, 2017 and 2016.
Stock-based compensation
Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.
Pursuant to ASC Topic 505-50, “Equity Based Payments to Non-employees”, for share-based payments to consultants and other third-parties, compensation expense is determined at the measurement date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.
Net loss per share of common stock
Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At May 31, 2017 and 2016, the Company has none and 430,000, respectively, potentially dilutive securities outstanding related to common stock warrants. Those potentially dilutive common stock equivalents were excluded from the dilutive loss per share calculation as they would be antidilutive due to the net loss.
Recently Issued Accounting Pronouncements
In February 2016, FASB issued ASU 2016-02, “Leases” (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new guidance will be effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods and is applied retrospectively. Early adoption is permitted. The Company does not believe the guidance will have a material impact on its financial statements.
In January 2017, the FASB issued ASU No. 2017-4, “Intangibles – Goodwill and Other” (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-4, an entity would perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-4 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements.
F- 11
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 2 – Significant and Critical Accounting Policies and Practices (continued)
Recently Issued Accounting Pronouncements (continued)
In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share” (Topic 260). The amendments in the update change the classification of certain equity-linked financial instruments (or embedded features) with down round features. The amendments also clarify existing disclosure requirements for equity-classified instruments. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260, Earnings Per Share, to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features would be subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company does not believe the guidance will have a material impact on its financial statements.
Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
Note 3 – Inventory
Inventory consisted of the following:
May 31,
2017 |
May 31,
2016 |
|||||||
Finished goods | $ | 82,494 | $ | 105,778 | ||||
Raw materials | 47,300 | 42,941 | ||||||
$ | 129,794 | $ | 148,719 |
In fiscal 2017 and 2016, the Company wrote down inventory for obsolescence and slow-moving inventory for $7,230 and $11,993, respectively, which is included in cost of sales.
Note 4 – Property and Equipment
Property and equipment, stated at cost, consisted of the following:
Estimated life |
May 31,
2017 |
May 31,
2016 |
||||||||
Furniture and fixtures | 5 years | $ | 5,398 | $ | 3,673 | |||||
Computer equipment | 3 years | 3,733 | - | |||||||
Less: Accumulated depreciation | (1,876 | ) | (490 | ) | ||||||
$ | 7,255 | $ | 3,183 |
Depreciation expense amounted to $1,386 and $490 for the years ended May 31, 2017 and 2016, respectively.
Note 5 – Loan and Note Payable
In December 2014, the Company entered into a promissory note agreement, providing for the issuance of a note in the principal amount of $100,000 to an unrelated party. The note was due on December 11, 2015. The annual interest rate for the note was 12%. The Note was convertible any time after the issuance date of the note at $0.10 per share. The Company granted the note holder 250,000 warrants in connection with the issuance of this note. The warrants had a term of 2 years from the date of grant and was exercisable at an exercise price of $1.00. The Company accounted for the warrants by using the relative fair value method. The total debt discount consisted of beneficial conversion feature of approximately $40,000 and relative fair value of the warrants of approximately $60,000 using a Black-Scholes model with the following assumptions: stock price at valuation date of $1.08 based on recent sales price of common stock in a private placement during that time, exercise price of $1.00, dividend yield of zero, years to maturity of 2.00, a risk free rate of 0.62%, and expected volatility of 103% using volatilities of similar companies. The Company recorded amortization of debt discount of $0 and $53,151 during the years ended May 31, 2017 and 2016, respectively.
F- 12
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 5 – Loan and Note Payable (continued)
In December 2015, the Company paid off a total of $103,000 and issued an additional negotiated 180,000 warrants in satisfaction of this note. The warrants had a term of 1 year from the date of grant and was exercisable at an exercise price of $1.38. The Company uses the Black-Scholes option pricing model to value the warrants using the following assumptions: stock price at valuation date of $0.25 based on recent PPM sales in December 2015, exercise price of $1.38, dividend yield of zero, years to maturity of 1.00, a risk free rate of 0.68%, and expected volatility of 108% using volatilities of similar companies. The Company valued these warrants at $2,482 which was included in the gain on debt settlement. The Company recorded a gain from settlement of debt of $6,551 in satisfaction of the principal note of $100,000 and accrued interest of $12,033. At May 31, 2017 and 2016, the outstanding principal balance of the note was $0.
In August 2016, the Company received loan proceeds of $675,000 from a related party. The Company may prepay the loan in full during the first 60 days without incurring any interest on the balance. However interest-free period shall cease on October 1, 2016 at which time the note accrues interest at a rate of 8% per annum. The Company paid off this loan in September 2016 and the Company did not incur any interest charges.
Note 6 – Stockholders’ Equity
Shares Authorized
The authorized capital of the Company consists of 100,000,000 shares of common stock, par value $0.0001 per share and 20,000,000 shares of preferred stock, par value $0.0001 per share.
Preferred Stock
The preferred stock may be issued from time to time in one or more series. The Board of Directors of the Company is expressly authorized to provide for the issuance of all or any of the share of the preferred stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed un the resolution adopted by the Board of Directors providing the issue of such shares. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.
Common Stock
During the year ended May 31, 2016, the Company sold an aggregate of 11,455,333 shares of its common stock at prices ranging from $0.03 to $0.25 per common share for proceeds of $792,459.
During the year ended May 31, 2017, the Company issued an aggregate of 19,249,500 shares of the Company’s common stock to various consultants pursuant to consulting agreements related to marketing and business advisory services. The term of the consulting agreements ranges from 1 month to 12 months. The Company valued these common shares at the fair value of $577,485 based on the sale of common stock in the recent private placement at $0.03 per common share and recognized the expense over the service periods. In connection with the issuance of these common shares, the Company recorded stock based compensation of $106,811 and $470,674 for the years ended May 31, 2017 and 2016, respectively.
During the year ended May 31, 2017, the Company sold an aggregate of 1,419,066 shares of its common stock at prices ranging from $0.25 to $0.62 per common share for proceeds of $422,501.
During the year ended May 31, 2017, the Company issued an aggregate of 109,000 shares of the Company’s common stock to various consultants pursuant to consulting agreements related to marketing and business advisory services. The term of the consulting agreements ranges from 1 month to 6 months. The Company valued these common shares at the fair value of $36,620 based on the sale of common stock in the recent private placements at prices ranging from $0.25 to $0.62 per common share. In connection with the issuance of these common shares, the Company recorded stock based compensation of $24,531 for the year ended May 31, 2017 and prepaid expense of $12,089 as of May 31, 2017 to be amortized over the term of its respective consulting agreements.
F- 13
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 6 – Stockholders’ Equity (continued)
Warrants
Stock warrant activities are summarized as follows:
Number of Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) |
Aggregate Intrinsic
Value |
|||||||||||||
Balance at May 31, 2015 | 250,000 | $ | 1.00 | 1.54 | $ | 0.59 | ||||||||||
Granted | 180,000 | 1.38 | 1.00 | 0.01 | ||||||||||||
Cancelled | - | - | - | - | ||||||||||||
Balance at May 31, 2016 | 430,000 | 1.15 | 0.53 | - | ||||||||||||
Granted | - | - | - | - | ||||||||||||
Expired | (430,000 | ) | - | - | - | |||||||||||
Balance at May 31, 2017 | - | - | - | - | ||||||||||||
Warrants exercisable at May 31, 2017 | - | $ | - | - | $ | - |
In December 2014, the Company entered into a promissory note agreement, providing for the issuance of a note in the principal amount of $100,000 to an unrelated party. The Company granted the note holder 250,000 warrants in connection with the issuance of this note. Additionally, in December 2015, the Company issued an additional 180,000 warrants in satisfaction of this note (see Note 5).
Note 7 – Commitments and Contingencies
In September 2016, the Company executed a lease agreement in connection with its office and warehouse facility in California under operating leases for a period of 37 months commencing in October 2016 and expiring in October 2019. The Company shall pay a monthly base rent starting at $6,782 plus a pro rata share of operating expenses. The base rent is subject to an annual increase beginning in October 2017 as defined in the lease agreement. Rent expense amounted to $69,467 and $49,600 for the years ended May 31, 2017 and 2016, respectively. Future minimum rental payments required under this operating lease are as follows:
Total | 1 Year | 2-3 Year | Thereafter | |||||||||||||
Operating lease | $ | 205,025 | $ | 83,096 | $ | 121,929 | $ | - | ||||||||
Total | $ | 205,025 | $ | 83,096 | $ | 121,929 | $ | - |
Note 8 – Related Party Transactions
In August 2016, the Company received loan proceeds of $675,000 from a related party. The Company may prepay the loan in full during the first 60 days without incurring any interest on the balance. However interest-free period shall cease on October 1, 2016 at which time the note accrues interest at a rate of 8% per annum. The Company paid off this loan in September 2016 and the Company did not incur any interest charges. The related party is an affiliated company managed by the brother of the Company’s Chief Executive Officer.
During the year ended May 31, 2016, the Company sold an aggregate of 4,400,000 shares of its common stock to an affiliated company at prices ranging from $0.03 to $0.07 per common share for proceeds of approximately $172,000. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
During the year ended May 31, 2016, the Company sold an aggregate of 3,430,000 shares of its common stock to an affiliated company at prices ranging from $0.03 to $0.07 per common share for proceeds of approximately $120,100. The affiliated company is managed by the Company’s Chief Executive Officer.
F- 14
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 8 – Related Party Transactions (continued)
During the year ended May 31, 2016, the Company issued 5,000,000 shares of the Company’s common stock to an affiliated company pursuant to a consulting agreement related to marketing and business advisory services. The term of the consulting agreement was for 12 months. The Company valued these common shares at the fair value of $150,000 based on the sale of common stock in the recent private placement at $0.03 per common share. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
During the year ended May 31, 2016, the Company issued 3,200,000 shares of the Company’s common stock to an affiliated company pursuant to a consulting agreement related to marketing and business advisory services. The term of the consulting agreement was for 12 months. The Company valued these common shares at the fair value of $96,000 based on the sale of common stock in the recent private placement at $0.03 per common share. The affiliated company is managed by the Company’s Chief Executive Officer.
During the year ended May 31, 2017, the Company sold 1,010,000 shares of its common stock to an affiliated company at $0.25 per common share for proceeds of approximately $253,000. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
Note 9 – Income taxes
The Company has incurred aggregate net operating losses of approximately $655,000 for income tax purposes as of May 31, 2017. The net operating loss carries forward for United States income taxes, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, through 2037. Management believes that the realization of the benefits from these losses appears not more than likely due to the Company’s limited operating history and continuing losses for United States income tax purposes. Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset to reduce the asset to zero. Management will review this valuation allowance periodically and make adjustments as necessary.
The table below summarizes the differences between the Company’s effective tax rate and the statutory federal rate as follows:
For
the
Year Ended May 31, 2017 |
For
the
Year Ended May 31, 2016 |
|||||||
Tax benefit computed at “expected” statutory rate of 34% | $ | (183,200 | ) | $ | (263,000 | ) | ||
State tax benefit of 9% | (48,500 | ) | (69,700 | ) | ||||
Non-deductible expenses: Stock-based compensation | 56,500 | 202,400 | ||||||
Non-deductible expenses: Non-cash interest expense | - | 23,900 | ||||||
Increase in valuation allowance | 175,200 | 106,400 | ||||||
Net income tax benefit | $ | - | $ | - |
The Company has a deferred tax asset which is summarized as follows at:
Deferred tax assets:
May
31,
2017 |
May
31,
2016 |
|||||||
Net operating loss carryover | $ | 281,600 | $ | 106,400 | ||||
Less: valuation allowance | (281,600 | ) | (106,400 | ) | ||||
Net deferred tax asset | $ | - | $ | - |
The Company provided a valuation allowance equal to the deferred income tax asset at May 31, 2017 and 2016 because it was not known whether future taxable income will be sufficient to utilize the loss carryforward. The increase in the allowance was $175,200 in fiscal 2017.
Additionally, the future utilization of the net operating loss carryforward to offset future taxable income may be subject to an annual limitation as a result of ownership changes that could occur in the future. If necessary, the deferred tax assets will be reduced by any carryforward that expires prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance.
The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2015 and 2016 Corporate Income Tax Returns are subject to Internal Revenue Service examination.
F- 15
REVIV3 PROCARE COMPANY
NOTES TO FINANCIAL STATEMENTS
MAY 31, 2017 AND 2016
Note 10 – Concentrations
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits, investments and cash equivalents instruments. The Company maintains its cash in bank deposits accounts. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At May 31, 2017 and 2016, the Company held cash of approximately $167,000 and $120,000, respectively, in excess of federally insured limits. The Company has not experienced any losses in such accounts at May 31, 2017 and 2016.
Concentration of Revenue and Supplier
During the year ended May 31, 2016 sales to four customers represented approximately 70% of the Company’s net sales at 24%, 17%, 16% and 13%. During the year ended May 31, 2017 sales to three customer represented approximately 48% of the Company’s net sales at 18%, 17% and 13%.
During the years ended May 31, 2017 and 2016 sales to customers outside the United States represented approximately 44% and 39% of the Company’s net sales, respectively.
As of May 31, 2017 and 2016, accounts receivable from four customer represented approximately 89% at 18%, 30%, 10% and 31%and two customers represented 91% at 62% and 29% of the accounts receivable, respectively.
The Company purchased inventories and products from two vendors totaling approximately $184,000 (73% of the purchases) and three vendors totaling $221,000 (73% of the purchases) during the years ended May 31, 2017 and 2016, respectively.
Note 11 - Subsequent Events
The Company has evaluated events and transactions for potential recognition or disclosure through October 6, 2017, the date the financial statements were available for issuance.
In June 2017, the Company issued an aggregate of 80,000 shares of the Company’s common stock to various consultants pursuant to consulting agreements related to marketing and business advisory services. The term of the consulting agreements ranges from 2 months to 6 months. The Company valued these common shares at the fair value of $20,000 based on the sale of common stock in the recent private placements at $0.25 per common share. In connection with the issuance of these common shares, the Company recorded prepaid expense of $20,000 to be amortized over the term of its respective consulting agreements.
Between September 27, 2017 and October 2, 2017, the Company sold an aggregate of 271,000 shares of its common stock at $0.40 per common share for proceeds of $108,400.
On September 26, 2017, the Company sold 100,000 shares of its common stock at $0.25 per common share for proceeds of $25,000.
On September 29, 2017, the Company sold 375,000 shares of its common stock to an affiliated company at $0.40 per common share for proceeds of approximately $150,000. The affiliated company is managed by the brother of the Company’s Chief Executive Officer.
F- 16
PART II-INFORMATION NOT REQUIRED IN PROSPECTUS
INDEMNIFICATION OF OFFICERS AND DIRECTORS
Pursuant to Section 607.0850 of the Delaware Revised Statutes, we have the power to indemnify any person made a party to any lawsuit by reason of being a director or officer of the Registrant, or serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Our Bylaws provide that the Registrant shall indemnify its directors and officers to the fullest extent permitted by Delaware law.
With regard to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of the Corporation in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the common shares being registered, we will, unless in the opinion of our counsel the matter has been settled by a controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by us is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such case.
OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following table is an itemization of all expenses, without consideration to future contingencies, incurred or expected to be incurred by our Corporation in connection with the issuance and distribution of the common shares being offered by this Prospectus. Items marked with an asterisk (*) represent estimated expenses. We have agreed to pay all the costs and expenses of this offering. Selling security holders will pay no offering expenses.
We outsourced legal, financial, and auditor services, as we do not have the operational size to handle such services in-house, for the purpose of structuring REVIV3 PROCARE COMPANY towards achieving operating status in the U.S. markets and registration with the OTCQB. Likewise, we outsourced governance matters, business and financial planning to two consultants, as we do not have the resources or the size to justify employing such professionals full-time.
Item | Amount | |||
SEC Registration Fee | $ | 22.35 | ||
Legal Fees and Expenses* | $ | 10,000 | ||
Accounting Fees and Expenses* | $ | 29,000 | ||
Miscellaneous* | $ | 750 | ||
Total* | $ | 39.772.50 |
* Estimated Figure
II- 1
RECENT SALES OF UNREGISTERED SECURITIES
Issuance of Common Stock
In the one (1) year prior to this Offering, we offered and sold 4,334,896 shares of common capital stock of the Company. None of the issuances involved underwriters, underwriting discounts or commissions. We relied upon Sections 4(2) of the Securities Act, and Rule 504 of the Securities Act of 1933, as amended for the offer and sale of the securities.
We believed these exemptions were available because:
● | we are not a blank check company; |
● | sales were not made by general solicitation or advertising; |
● | all certificates had restrictive legends; |
● | sales were made to persons with a pre-existing relationship with one or more of: (i) our chief executive officer, president and director, Mr. Jeff Toghraie, at the time of the offer and sale. |
We relied upon Section 4(2) of the Securities Act of 1933, as amended for the above issuances.
We believed that Section 4(2) of the Securities Act of 1933 was available because:
● | None of these issuances involved underwriters, underwriting discounts or commissions. |
● | Restrictive legends were and will be placed on all certificates issued as described above. |
● | The distribution did not involve general solicitation or advertising. |
● | The distributions were made only to investors who were sophisticated enough to evaluate the risks of the investment. |
In connection with the above transactions, although the investors may have also been accredited, we provided the following to all investors:
● | Access to all our books and records. |
● | Access to documents relating to our operations. |
● | The opportunity to obtain any additional information, including information relating to all of our agreements with third parties which were only oral and not written, to the extent we possessed such information, and including all information necessary to verify the accuracy of the information to which the investors were given access. |
Prospective investors were invited to review at our offices at any reasonable hour, after reasonable advance notice, any materials available to us concerning our business.
II- 2
EXHIBITS
Incorporated by reference | ||||||||||||
Exhibit | Filed | Period | Filing | |||||||||
Number | Exhibit Description | herewith | Form | ending | Exhibit | date | ||||||
3.1 | Articles of Incorporation filed with the state of Delaware on May 21, 2015 | X | ||||||||||
3.2 | Bylaws | X | ||||||||||
3.3 | Certificate of Amendment filed in the state of Delaware on June 9, 2015 | X | ||||||||||
4.2 | Form of common stock Certificate of REVIV3 PROCARE COMPANY (1) | X | ||||||||||
5.1 | Legal Opinion of Eilers Law Group, P.A. | X | ||||||||||
10.1 | Contribution Agreement between Reviv3 Procare, LLC and Reviv3 Procare Company, dated June 1, 2015 | X | ||||||||||
23.1 | Consent of Salberg & Company, P.A. | X | ||||||||||
23.2 | Consent of Eilers Law Group, P.A. (included in Exhibit 5.1) | X |
(1) | Information pertaining to our common stock is contained in our Articles of Incorporation and Bylaws. |
All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.
II- 3
UNDERTAKINGS
The undersigned registrant hereby undertakes
1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
i. | To include any Prospectus required by section 10(a)(3) of the Securities Act of 1933; |
ii. | To reflect in the Prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of Prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than twenty percent (20%) change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement. |
iii. | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
4. That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
i. | Any Preliminary Prospectus or Prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
ii. | Any free writing Prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
iii. | The portion of any other free writing Prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
iv. | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
5. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: Each Prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than Prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or Prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or Prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or Prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
6. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of the corporation in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by a controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by us is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such case.
II- 4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in El Monte, California on October 6, 2017.
REVIV3 PROCARE COMPANY | ||
By: | /s/ Jeff Toghraie | |
Jeff Toghraie | ||
Chief Executive Officer |
In accordance with the requirements of the Securities Act of 1933, this registration statement was signed by the following persons in the capacities and on the dates stated:
NAME | TITLE | DATE | ||
/s/ Jeff Toghraie | Chief Executive Officer & Director | October 6, 2017 | ||
Jeff Toghraie | ||||
/s/ Nancy Hundt | Director | October 6, 2017 | ||
Nancy Hundt |
II-5
Exhibit 3.1
Delaware
PAGE 1
The First State
I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF “REVIV3 PROCARE COMPANY”, FILED IN THIS OFFICE ON THE TWENTY-FIRST DAY OF MAY, A.D. 2015, AT 3:24 O’CLOCK P.M.
A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.
5752771 8100 | /s/ Jeffrey W. Bullock | |
150736849 |
Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 2403745 |
|
You may verify this certificate online
at corp.delaware.gov/authver.shtml |
DATE: 05-22-15 |
State
of Delaware
Delivered
03:24 PM 05/21/2015
|
STATE OF DELAWARE
CERTIFICATE OF INCORPORATION
A STOCK CORPORATION
● | First: The name of this Corporation is REVIV3 PROCARE COMPANY | |
● | Second: Its registered office in the State of Delaware is to be located at 1209 Orange Street, in the City of Wilmington County of New Castle Zip Code 19801. The registered agent in charge thereof is The Corporation Trust Company | |
Third: The purpose of the corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware. |
● | Fourth: The amount of the total stock of this corporation is authorized to issue is 100,000,000 shares (number of authorized shares) with a par value of 0.0001 per share. | |
● |
Fifth: The name and mailing address of the incorporator are as follows:
Name Michael Peng
|
|
Mailing
Address 10100 Santa Monica Blvd.,
Suite 2200 |
||
Los Zip Code 90067 |
● | I, The Undersigned, for the purpose of forming a corporation under the laws of the State of Delaware, do make, file and record this Certificate, and do certify that the facts herein stated arc true, and I have accordingly hereunto set my hand this 20th day of May ___, A.D. 2015 |
BY: | /s/ Michael Pen g | |
(Incorporator) | ||
NAME: | J Michael Peng | |
(type or print) |
REVIV3 PROCARE, LLC
1600 Dove Street, Suite 450
Newport Beach, CA 92660
May 20, 2014
Delaware Secretary of State
Division of Corporations
John G. Townsend Bldg.
401 Federal Street, - Suite 4
Dover, DE 19901
Re: Formation of Reviv3 Procare Company
Dear Sir/Madam:
Please be advised that the undersigned, being the member of Reviv3 Procare, LLC, a Delaware limited liability company, hereby consent to the formation of a Delaware corporation with the name of Reviv3 Procare Company. The entities are affiliates and will be under common control.
Very truly yours, | ||
Name: | Roger Davis | |
Title: | Member |
Exhibit 3.2
BYLAWS OF
REVIV3 PROCARE COMPANY
Adopted May 21, 2015
TABLE OF CONTENTS
Page | |||
ARTICLE I — MEETINGS OF STOCKHOLDERS | 1 | ||
1.1 | Place of Meetings | 1 | |
1.2 | Annual Meeting | 1 | |
1.3 | Special Meeting | 1 | |
1.4 | Notice of Stockholders’ Meetings | 1 | |
1.5 | Quorum | 2 | |
1.6 | Adjourned Meeting; Notice | 2 | |
1.7 | Conduct of Business | 2 | |
1.8 | Voting | 2 | |
1.9 | Stockholder Action by Written Consent Without a Meeting | 3 | |
1.10 | Record Date for Stockholder Notice; Voting; Giving Consents | 4 | |
1.11 | Proxies | 4 | |
1.12 | List of Stockholders Entitled to Vote | 5 | |
ARTICLE II — DIRECTORS | 5 | ||
2.1 | Powers | 5 | |
2.2 | Number of Directors | 5 | |
2.3 | Election, Qualification and Term of Office of Directors | 5 | |
2.4 | Resignation and Vacancies | 5 | |
2.5 | Place of Meetings; Meetings by Telephone | 6 | |
2.6 | Conduct of Business | 6 | |
2.7 | Regular Meetings | 6 | |
2.8 | Special Meetings; Notice | 7 | |
2.9 | Quorum; Voting | 7 | |
2.10 | Board Action by Written Consent Without a Meeting | 7 | |
2.11 | Fees and Compensation of Directors | 7 | |
2.12 | Removal of Directors | 8 | |
ARTICLE III — COMMITTEES | 8 | ||
3.1 | Committees of Directors | 8 | |
3.2 | Committee Minutes | 8 | |
3.3 | Meetings and Actions of Committees | 8 | |
3.4 | Subcommittees | 9 | |
ARTICLE IV — OFFICERS | 9 | ||
4.1 | Officers | 9 | |
4.2 | Appointment of Officers | 9 | |
4.3 | Subordinate Officers | 9 | |
4.4 | Removal and Resignation of Officers | 9 | |
4.5 | Vacancies in Offices | 9 | |
4.6 | Representation of Shares of Other Corporations | 9 | |
4.7 | Authority and Duties of Officers | 10 |
- i - |
TABLE OF CONTENTS
(Continued)
Page | |||
ARTICLE V — INDEMNIFICATION | 10 | ||
5.1 | Indemnification of Directors and Officers in Third Party Proceedings | 10 | |
5.2 | Indemnification of Directors and Officers in Actions by or in the Right of the Company | 10 | |
5.3 | Successful Defense | 10 | |
5.4 | Indemnification of Others | 11 | |
5.5 | Advance Payment of Expenses | 11 | |
5.6 | Limitation on Indemnification | 11 | |
5.7 | Determination; Claim | 11 | |
5.8 | Non-Exclusivity of Rights | 12 | |
5.9 | Insurance | 12 | |
5.10 | Survival | 12 | |
5.11 | Effect of Repeal or Modification | 12 | |
5.12 | Certain Definitions | 12 | |
ARTICLE VI — STOCK | 12 | ||
6.1 | Stock Certificates; Partly Paid Shares | 12 | |
6.2 | Special Designation on Certificates | 13 | |
6.3 | Lost Certificates | 13 | |
6.4 | Dividends | 13 | |
6.5 | Stock Transfer Agreements | 14 | |
6.6 | Registered Stockholders | 14 | |
6.7 | Transfers | 14 | |
ARTICLE VII — MANNER OF GIVING NOTICE AND WAIVER | 14 | ||
7.1 | Notice of Stockholder Meetings | 14 | |
7.2 | Notice by Electronic Transmission | 14 | |
7.3 | Notice to Stockholders Sharing an Address | 15 | |
7.4 | Notice to Person with Whom Communication is Unlawful | 15 | |
7.5 | Waiver of Notice | 15 | |
ARTICLE VIII — GENERAL MATTERS | 16 | ||
8.1 | Fiscal Year | 16 | |
8.2 | Seal | 16 | |
8.3 | Annual Report | 16 | |
8.4 | Construction; Definitions | 16 | |
ARTICLE IX — AMENDMENTS | 16 |
- ii - |
BYLAWS
ARTICLE I — MEETINGS OF STOCKHOLDERS
1.1 Place of Meetings . Meetings of stockholders of Reviv3 Procare Company (the “ Company ”) shall be held at any place, within or outside the State of Delaware, determined by the Company’s board of directors (the “ Board ”). The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the Delaware General Corporation Law (the “ DGCL ”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the Company’s principal executive office.
1.2 Annual Meeting . An annual meeting of stockholders shall be held for the election of directors at such date and time as may be designated by resolution of the Board from time to time. Any other proper business may be transacted at the annual meeting. The Company shall not be required to hold an annual meeting of stockholders, provided that (i) the stockholders are permitted to act by written consent under the Company’s certificate of incorporation and these bylaws, (ii) the stockholders take action by written consent to elect directors and (iii) the stockholders unanimously consent to such action or, if such consent is less than unanimous, all of the directorships to which directors could be elected at an annual meeting held at the effective time of such action are vacant and are filled by such action.
1.3 Special Meeting . A special meeting of the stockholders may be called at any time by the Board, Chairperson of the Board, Chief Executive Officer or President (in the absence of a Chief Executive Officer) or by one or more stockholders holding shares in the aggregate entitled to cast not less than 10% of the votes at that meeting.
If any person(s) other than the Board calls a special meeting, the request shall:
(i) be in writing;
(ii) specify the time of such meeting and the general nature of the business proposed to be transacted; and
(iii) be delivered personally or sent by registered mail or by facsimile transmission to the Chairperson of the Board, the Chief Executive Officer, the President (in the absence of a Chief Executive Officer) or the Secretary of the Company.
The officer(s) receiving the request shall cause notice to be promptly given to the stockholders entitled to vote at such meeting, in accordance with these bylaws, that a meeting will be held at the time requested by the person or persons calling the meeting. No business may be transacted at such special meeting other than the business specified in such notice to stockholders. Nothing contained in this paragraph of this section 1.3 shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board may be held.
1.4 Notice of Stockholders’ Meetings . Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Except as otherwise provided in the DGCL, the certificate of incorporation or these bylaws, the written notice of any meeting of stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting.
1.5 Quorum . Except as otherwise provided by law, the certificate of incorporation or these bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of shares of stock having a majority of the votes which could be cast by the holders of all outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. Where a separate vote by a class or series or classes or series is required, a majority of the outstanding shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter, except as otherwise provided by law, the certificate of incorporation or these bylaws.
If, however, such quorum is not present or represented at any meeting of the stockholders, then either (i) the chairperson of the meeting, or (ii) the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have the power to adjourn the meeting from time to time, in the manner provided in section 1.6 , until a quorum is present or represented.
1.6 Adjourned Meeting; Notice . Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Company may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
1.7 Conduct of Business . Meetings of stockholders shall be presided over by the Chairperson of the Board, if any, or in his or her absence by the Vice Chairperson of the Board, if any, or in the absence of the foregoing persons by the Chief Executive Officer, or in the absence of the foregoing persons by the President, or in the absence of the foregoing persons by a Vice President, or in the absence of the foregoing persons by a chairperson designated by the Board, or in the absence of such designation by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting. The chairperson of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of business.
1.8 Voting . The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of section 1.10 of these bylaws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL.
Except as may be otherwise provided in the certificate of incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of capital stock held by such stockholder which has voting power upon the matter in question. Voting at meetings of stockholders need not be by written ballot and, unless otherwise required by law, need not be conducted by inspectors of election unless so determined by the holders of shares of stock having a majority of the votes which could be cast by the holders of all outstanding shares of stock entitled to vote thereon which are present in person or by proxy at such meeting. If authorized by the Board, such requirement of a written ballot shall be satisfied by a ballot submitted by electronic transmission (as defined in section 7.2 of these bylaws), provided that any such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the stockholder or proxy holder.
- 2 - |
Except as otherwise required by law, the certificate of incorporation or these bylaws, in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders. Except as otherwise required by law, the certificate of incorporation or these bylaws, directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Where a separate vote by a class or series or classes or series is required, in all matters other than the election of directors, the affirmative vote of the majority of shares of such class or series or classes or series present in person or represented by proxy at the meeting shall be the act of such class or series or classes or series, except as otherwise provided by law, the certificate of incorporation or these bylaws.
1.9 Stockholder Action by Written Consent Without a Meeting . Unless otherwise provided in the certificate of incorporation, any action required by the DGCL to be taken at any annual or special meeting of stockholders of a corporation, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice, and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.
An electronic transmission (as defined in section 7.2 ) consenting to an action to be taken and transmitted by a stockholder or proxy holder, or by a person or persons authorized to act for a stockholder or proxy holder, shall be deemed to be written, signed and dated for purposes of this section, provided that any such electronic transmission sets forth or is delivered with information from which the Company can determine (i) that the electronic transmission was transmitted by the stockholder or proxy holder or by a person or persons authorized to act for the stockholder or proxy holder and (ii) the date on which such stockholder or proxy holder or authorized person or persons transmitted such electronic transmission.
In the event that the Board shall have instructed the officers of the Company to solicit the vote or written consent of the stockholders of the Company, an electronic transmission of a stockholder written consent given pursuant to such solicitation may be delivered to the Secretary or the President of the Company or to a person designated by the Secretary or the President. The Secretary or the President of the Company or a designee of the Secretary or the President shall cause any such written consent by electronic transmission to be reproduced in paper form and inserted into the corporate records.
Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Company as provided in Section 228 of the DGCL. In the event that the action which is consented to is such as would have required the filing of a certificate under any provision of the DGCL, if such action had been voted on by stockholders at a meeting thereof, the certificate filed under such provision shall state, in lieu of any statement required by such provision concerning any vote of stockholders, that written consent has been given in accordance with Section 228 of the DGCL.
- 3 - |
1.10 Record Date for Stockholder Notice; Voting; Giving Consents . In order that the Company may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which record date:
(i) in the case of determination of stockholders entitled to notice of or to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law, not be more than sixty nor less than ten days before the date of such meeting;
(ii) in the case of determination of stockholders entitled to express consent to corporate action in writing without a meeting, shall not be more than ten days after the date upon which the resolution fixing the record date is adopted by the Board; and
(iii) in the case of determination of stockholders for any other action, shall not be more than 60 days prior to such other action.
If no record date is fixed by the Board:
(i) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held;
(ii) the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting when no prior action of the Board is required by law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Company in accordance with applicable law, or, if prior action by the Board is required by law, shall be at the close of business on the day on which the Board adopts the resolution taking such prior action; and
(iii) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.
A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, provided that the Board may fix a new record date for the adjourned meeting.
- 4 - |
1.11 Proxies . Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL.
1.12 List of Stockholders Entitled to Vote . The officer who has charge of the stock ledger of the Company shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Company shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the Company’s principal place of business. In the event that the Company determines to make the list available on an electronic network, the Company may take reasonable steps to ensure that such information is available only to stockholders of the Company. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be examined by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting.
ARTICLE II — DIRECTORS
2.1 Powers . The business and affairs of the Company shall be managed by or under the direction of the Board, except as may be otherwise provided in the DGCL or the certificate of incorporation.
2.2 Number of Directors . The Board shall consist of one or more members, each of whom shall be a natural person. Unless the certificate of incorporation fixes the number of directors, the number of directors shall be determined from time to time by resolution of the Board. No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires.
2.3 Election, Qualification and Term of Office of Directors . Except as provided in section 2.4 of these bylaws, and subject to sections 1.2 and 1.9 of these bylaws, directors shall be elected at each annual meeting of stockholders. Directors need not be stockholders unless so required by the certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws may prescribe other qualifications for directors. Each director shall hold office until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal.
2.4 Resignation and Vacancies . Any director may resign at any time upon notice given in writing or by electronic transmission to the Company. A resignation is effective when the resignation is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events. A resignation which is conditioned upon the director failing to receive a specified vote for reelection as a director may provide that it is irrevocable. Unless otherwise provided in the certificate of incorporation or these bylaws, when one or more directors resign from the Board, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective.
- 5 - |
Unless otherwise provided in the certificate of incorporation or these bylaws:
(i) Vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.
(ii) Whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the certificate of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected.
If at any time, by reason of death or resignation or other cause, the Company should have no directors in office, then any officer or any stockholder or an executor, administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of a stockholder, may call a special meeting of stockholders in accordance with the provisions of the certificate of incorporation or these bylaws, or may apply to the Court of Chancery for a decree summarily ordering an election as provided in Section 211 of the DGCL.
If, at the time of filling any vacancy or any newly created directorship, the directors then in office constitute less than a majority of the whole Board (as constituted immediately prior to any such increase), the Court of Chancery may, upon application of any stockholder or stockholders holding at least 10% of the voting stock at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in office as aforesaid, which election shall be governed by the provisions of Section 211 of the DGCL as far as applicable.
A director elected to fill a vacancy shall be elected for the unexpired term of his or her predecessor in office and until such director’s successor is elected and qualified, or until such director’s earlier death, resignation or removal.
2.5 Place of Meetings; Meetings by Telephone . The Board may hold meetings, both regular and special, either within or outside the State of Delaware.
Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.
2.6 Conduct of Business . Meetings of the Board shall be presided over by the Chairperson of the Board, if any, or in his or her absence by the Vice Chairperson of the Board, if any, or in the absence of the foregoing persons by a chairperson designated by the Board, or in the absence of such designation by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.
2.7 Regular Meetings . Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board.
- 6 - |
2.8 Special Meetings; Notice . Special meetings of the Board for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer, the President, the Secretary or any two directors.
Notice of the time and place of special meetings shall be:
(i) delivered personally by hand, by courier or by telephone;
(ii) sent by United States first-class mail, postage prepaid;
(iii) sent by facsimile; or
(iv) sent by electronic mail, directed to each director at that director’s address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the Company’s records.
If the notice is (i) delivered personally by hand, by courier or by telephone, (ii) sent by facsimile or (iii) sent by electronic mail, it shall be delivered or sent at least 24 hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four days before the time of the holding of the meeting. Any oral notice may be communicated to the director. The notice need not specify the place of the meeting (if the meeting is to be held at the Company’s principal executive office) nor the purpose of the meeting.
2.9 Quorum; Voting . At all meetings of the Board, a majority of the total authorized number of directors shall constitute a quorum for the transaction of business. If a quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken is approved by at least a majority of the required quorum for that meeting.
The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws.
If the certificate of incorporation provides that one or more directors shall have more or less than one vote per director on any matter, every reference in these bylaws to a majority or other proportion of the directors shall refer to a majority or other proportion of the votes of the directors.
2.10 Board Action by Written Consent Without a Meeting . Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.
2.11 Fees and Compensation of Directors . Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board shall have the authority to fix the compensation of directors.
- 7 - |
2.12 Removal of Directors . Unless otherwise restricted by statute, the certificate of incorporation or these bylaws, any director or the entire Board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.
No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of such director’s term of office.
ARTICLE III — COMMITTEES
3.1 Committees of Directors . The Board may designate one or more committees, each committee to consist of one or more of the directors of the Company. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Company, and may authorize the seal of the Company to be affixed to all papers that may require it; but no such committee shall have the power or authority to (i) approve or adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any bylaw of the Company.
3.2 Committee Minutes . Each committee shall keep regular minutes of its meetings and report the same to the Board when required.
3.3 Meetings and Actions of Committees . Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:
(i) section 2.5 (Place of Meetings; Meetings by Telephone);
(ii) section 2.7 (Regular Meetings);
(iii) section 2.8 (Special Meetings; Notice);
(iv) section 2.9 (Quorum; Voting);
(v) section 2.10 (Board Action by Written Consent Without a Meeting); and
(vi) section 7.5 (Waiver of Notice)
with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members. However :
(i) the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;
(ii) special meetings of committees may also be called by resolution of the Board; and
- 8 - |
(iii) notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend all meetings of the committee. The Board may adopt rules for the government of any committee not inconsistent with the provisions of these bylaws.
Any provision in the certificate of incorporation providing that one or more directors shall have more or less than one vote per director on any matter shall apply to voting in any committee or subcommittee, unless otherwise provided in the certificate of incorporation or these bylaws.
3.4 Subcommittees . Unless otherwise provided in the certificate of incorporation, these bylaws or the resolutions of the Board designating the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.
ARTICLE IV — OFFICERS
4.1 Officers . The officers of the Company shall be a President and a Secretary. The Company may also have, at the discretion of the Board, a Chairperson of the Board, a Vice Chairperson of the Board, a Chief Executive Officer, one or more Vice Presidents, a Chief Financial Officer, a Treasurer, one or more Assistant Treasurers, one or more Assistant Secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by the same person.
4.2 Appointment of Officers . The Board shall appoint the officers of the Company, except such officers as may be appointed in accordance with the provisions of section 4.3 of these bylaws.
4.3 Subordinate Officers . The Board may appoint, or empower the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President, to appoint, such other officers and agents as the business of the Company may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board may from time to time determine.
4.4 Removal and Resignation of Officers . Any officer may be removed, either with or without cause, by an affirmative vote of the majority of the Board at any regular or special meeting of the Board or, except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.
Any officer may resign at any time by giving written notice to the Company. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Company under any contract to which the officer is a party.
4.5 Vacancies in Offices . Any vacancy occurring in any office of the Company shall be filled by the Board or as provided in section 4.3 .
4.6 Representation of Shares of Other Corporations . Unless otherwise directed by the Board, the President or any other person authorized by the Board or the President is authorized to vote, represent and exercise on behalf of the Company all rights incident to any and all shares of any other corporation or corporations standing in the name of the Company. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.
- 9 - |
4.7 Authority and Duties of Officers . Except as otherwise provided in these bylaws, the officers of the Company shall have such powers and duties in the management of the Company as may be designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board.
ARTICLE V — INDEMNIFICATION
5.1 Indemnification of Directors and Officers in Third Party Proceedings . Subject to the other provisions of this Article V , the Company shall indemnify, to the fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”) (other than an action by or in the right of the Company) by reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person’s conduct was unlawful.
5.2 Indemnification of Directors and Officers in Actions by or in the Right of the Company . Subject to the other provisions of this Article V , the Company shall indemnify, to the fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
5.3 Successful Defense . To the extent that a present or former director or officer of the Company has been successful on the merits or otherwise in defense of any action, suit or proceeding described in section 5.1 or section 5.2 , or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.
- 10 - |
5.4 Indemnification of Others . Subject to the other provisions of this Article V , the Company shall have power to indemnify its employees and agents to the extent not prohibited by the DGCL or other applicable law. The Board shall have the power to delegate to such person or persons the determination of whether employees or agents shall be indemnified.
5.5 Advance Payment of Expenses . Expenses (including attorneys’ fees) incurred by an officer or director of the Company in defending any Proceeding shall be paid by the Company in advance of the final disposition of such Proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on behalf of the person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under this Article V or the DGCL. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as the Company deems appropriate. The right to advancement of expenses shall not apply to any Proceeding for which indemnity is excluded pursuant to these bylaws.
5.6 Limitation on Indemnification . Subject to the requirements in section 5.3 and the DGCL, the Company shall not be obligated to indemnify any person pursuant to this Article V in connection with any Proceeding (or any part of any Proceeding):
(i) for which payment has actually been made to or on behalf of such person under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid;
(ii) initiated by such person, including any Proceeding (or any part of any Proceeding) initiated by such person against the Company or its directors, officers, employees, agents or other indemnitees, unless (a) the Board authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (b) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (c) otherwise required to be made under section 5.7 or (d) otherwise required by applicable law; or
(iii) if prohibited by applicable law.
5.7 Determination; Claim . If a claim for indemnification or advancement of expenses under this Article V is not paid by the Company or on its behalf within 90 days after receipt by the Company of a written request therefor, the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of expenses. To the extent not prohibited by law, the Company shall indemnify such person against all expenses actually and reasonably incurred by such person in connection with any action for indemnification or advancement of expenses from the Company under this Article V , to the extent such person is successful in such action, and, if requested by such person, shall advance such expenses to such person, subject to the provisions of Section 5.5. In any such suit, the Company shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant is not entitled to the requested indemnification or advancement of expenses.
- 11 - |
5.8 Non-Exclusivity of Rights . The indemnification and advancement of expenses provided by, or granted pursuant to, this Article V shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the certificate of incorporation or any statute, bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office. The Company is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or other applicable law.
5.9 Insurance . The Company may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL.
5.10 Survival . The rights to indemnification and advancement of expenses conferred by this Article V shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
5.11 Effect of Repeal or Modification . Any amendment, alteration or repeal of this Article V shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to such amendment, alteration or repeal.
5.12 Certain Definitions . For purposes of this Article V , references to the “ Company ” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article V with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued. For purposes of this Article V , references to “ other enterprises ” shall include employee benefit plans; references to “ fines ” shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to “ serving at the request of the Company ” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “ not opposed to the best interests of the Company ” as referred to in this Article V .
- 12 - |
ARTICLE VI — STOCK
6.1 Stock Certificates; Partly Paid Shares . The shares of the Company shall be represented by certificates, provided that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Company. Every holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of the Company by the Chairperson of the Board or Vice-Chairperson of the Board, or the President or a Vice-President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary of the Company representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Company with the same effect as if such person were such officer, transfer agent or registrar at the date of issue. The Company shall not have power to issue a certificate in bearer form.
The Company may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Company in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the Company shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.
6.2 Special Designation on Certificates . If the Company is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the Company shall issue to represent such class or series of stock; provided that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate that the Company shall issue to represent such class or series of stock, a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the Company shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this section 6.2 or Sections 156, 202(a) or 218(a) of the DGCL or with respect to this section 6.2 a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.
6.3 Lost Certificates . Except as provided in this section 6.3 , no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Company and cancelled at the same time. The Company may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Company may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the Company a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.
6.4 Dividends . The Board, subject to any restrictions contained in the certificate of incorporation or applicable law, may declare and pay dividends upon the shares of the Company’s capital stock. Dividends may be paid in cash, in property, or in shares of the Company’s capital stock, subject to the provisions of the certificate of incorporation.
- 13 - |
The Board may set apart out of any of the funds of the Company available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve.
6.5 Stock Transfer Agreements . The Company shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Company to restrict the transfer of shares of stock of the Company of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.
6.6 Registered Stockholders . The Company:
(i) shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner;
(ii) shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and
(iii) shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
6.7 Transfers . Transfers of record of shares of stock of the Company shall be made only upon its books by the holders thereof, in person or by an attorney duly authorized, and, if such stock is certificated, upon the surrender of a certificate or certificates for a like number of shares, properly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer.
ARTICLE VII — MANNER OF GIVING NOTICE AND WAIVER
7.1 Notice of Stockholder Meetings . Notice of any meeting of stockholders, if mailed, is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the Company’s records. An affidavit of the Secretary or an Assistant Secretary of the Company or of the transfer agent or other agent of the Company that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
7.2 Notice by Electronic Transmission . Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the certificate of incorporation or these bylaws, any notice to stockholders given by the Company under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the Company. Any such consent shall be deemed revoked if:
(i) the Company is unable to deliver by electronic transmission two consecutive notices given by the Company in accordance with such consent; and
(ii) such inability becomes known to the Secretary or an Assistant Secretary of the Company or to the transfer agent, or other person responsible for the giving of notice.
However, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.
- 14 - |
Any notice given pursuant to the preceding paragraph shall be deemed given:
(i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;
(ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice;
(iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and
(iv) if by any other form of electronic transmission, when directed to the stockholder.
An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Company that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
An “ electronic transmission ” means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.
Notice by a form of electronic transmission shall not apply to Sections 164, 296, 311, 312 or 324 of the DGCL.
7.3 Notice to Stockholders Sharing an Address . Except as otherwise prohibited under the DGCL, without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Company under the provisions of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Any such consent shall be revocable by the stockholder by written notice to the Company. Any stockholder who fails to object in writing to the Company, within 60 days of having been given written notice by the Company of its intention to send the single notice, shall be deemed to have consented to receiving such single written notice.
7.4 Notice to Person with Whom Communication is Unlawful . Whenever notice is required to be given, under the DGCL, the certificate of incorporation or these bylaws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Company is such as to require the filing of a certificate under the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.
7.5 Waiver of Notice . Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the certificate of incorporation or these bylaws.
- 15 - |
ARTICLE VIII — GENERAL MATTERS
8.1 Fiscal Year . The fiscal year of the Company shall be fixed by resolution of the Board and may be changed by the Board.
8.2 Seal . The Company may adopt a corporate seal, which shall be in such form as may be approved from time to time by the Board. The Company may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.
8.3 Annual Report . The Company shall cause an annual report to be sent to the stockholders of the Company to the extent required by applicable law. If and so long as there are fewer than 100 holders of record of the Company’s shares, the requirement of sending an annual report to the stockholders of the Company is expressly waived (to the extent permitted under applicable law).
8.4 Construction; Definitions . Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term “person” includes both a corporation and a natural person.
ARTICLE IX — AMENDMENTS
These bylaws may be adopted, amended or repealed by the stockholders entitled to vote. However, the Company may, in its certificate of incorporation, confer the power to adopt, amend or repeal bylaws upon the directors. The fact that such power has been so conferred upon the directors shall not divest the stockholders of the power, nor limit their power to adopt, amend or repeal bylaws.
A bylaw amendment adopted by stockholders which specifies the votes that shall be necessary for the election of directors shall not be further amended or repealed by the Board.
- 16 -
Exhibit 3.3
AMENDED
AND RESTATED
OF
REVIV3 PROCARE COMPANY
Reviv3 Procare Company, a corporation organized and existing under the General Corporation Law of the State of Delaware (the “ Corporation ”), does hereby certify that:
1. | The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on May 21, 2015. |
2. | The Corporation has not issued or received payment for any of its stock. |
3. | The Amended and Restated Certificate of Incorporation in the form attached hereto as Exhibit A has been duly adopted in accordance with the provisions of Section 241 of the General Corporation Law of the State of Delaware by the Board of Directors of the Corporation. |
4. | The Amended and Restated Certificate of Incorporation so adopted reads in full as set forth in Exhibit A attached hereto, and is incorporated herein by this reference. |
IN WITNESS WHEREOF, Reviv3 Procare Company has caused this Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer on this 1 st day of June, 2015.
Reviv3 Procare Company | ||
By: | /s/ Roger Davis | |
Roger Davis | ||
Chief Executive Officer |
EXHIBIT A
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
REVIV3 PROCARE COMPANY
ARTICLE I.
The name of this corporation is Reviv3 Procare Company (the “ Corporation ”).
ARTICLE II.
The address of the registered office of the corporation in the State of Delaware is 1209 Orange Street, Wilmington, Delaware, County of New Castle, 19801. The name of the registered agent of the corporation at such address is The Corporation Trust Company.
ARTICLE III.
The nature of the business of the Corporation and the objects or purposes to be transacted, promoted or carried on by it are to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the “ General Corporation Law ”).
ARTICLE IV.
A. Classes of Stock . This Corporation is authorized to issue two classes of stock to be designated, respectively, “ Common Stock ” and “ Preferred Stock .” The total number of shares that this Corporation is authorized to issue is One Hundred Twenty Million (120,000,000) shares, of which One Hundred Million (100,000,000) shares shall be Common Stock, each with a par value of $0.0001 per share, and Twenty Million (20,000,000) shares shall be Preferred Stock, each with a par value of $0.0001 per share. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote.
B. Preferred Stock . The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Corporation (the “ Board of Directors ”) is expressly authorized to provide for the issue of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers, and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issue of such shares and as may be permitted by the General Corporation Law of the State of Delaware. The Board of Directors is also expressly authorized to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.
C. Voting Power . Except as otherwise required by law, or as otherwise fixed by resolution or resolutions of the Board of Directors with respect to one or more series of Preferred Stock, the entire voting power and all voting rights shall be vested exclusively in the Common Stock, and each stockholder of the Corporation who at the time possesses voting power for any purpose shall be entitled to one vote for each share of such stock standing in his name on the books of the Corporation. Unless required by law, there shall be no cumulative voting.
ARTICLE V.
Except as may otherwise be provided in this Amended and Restated Certificate of Incorporation, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter or repeal the Bylaws of the Corporation.
ARTICLE VI.
For the management of the business and for the conduct of the affairs of the Corporation, and in further definition, limitation, and regulation of the powers of the Corporation and of its directors and of its stockholders or any class thereof, as the case may be, it is further provided:
1. The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of Directors. Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
2. After the original or other Bylaws of the Corporation have been adopted, amended, or repealed, as the case may be, in accordance with the provisions of Section 109 of the General Corporation Law, and, after the Corporation has received any payment for any of its stock, the power to adopt, amend, or repeal the Bylaws of the Corporation may be exercised by the Board of Directors of the Corporation; provided, however, that any provision for the classification of directors of the Corporation for staggered terms pursuant to Section 141(d) of the General Corporation Law shall be set forth in an initial Bylaw or in a Bylaw adopted by the stockholders of the Corporation entitled to vote unless provisions for such classification shall be set forth in this Amended and Restated Certificate of Incorporation.
3. Whenever the Corporation shall be authorized to issue only one class of stock, each outstanding share shall entitle the holder thereof to notice of, and the right to vote at, any meeting of stockholders. Whenever the Corporation shall be authorized to issue more than one class of stock, no outstanding share of any class of stock which is denied voting power under the provisions of this Amended and Restated Certificate of Incorporation shall entitle the holder thereof to the right to vote at any meeting of stockholders except as the provisions of Section 242(b)(2) of the General Corporation Law shall otherwise require; provided, that no share of any such class which is otherwise denied voting power shall entitle the holder thereof to vote upon the increase or decrease in the number of authorized shares of said class.
ARTICLE VII.
Whenever a compromise or arrangement is proposed between this Corporation and its creditors or any class of them and/or between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this Corporation or of any creditor or stockholder thereof, or on the application of any receiver or receivers appointed for this Corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this Corporation under the provisions of Section 279 of Title 8 of the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this Corporation, as the case may be, and also on this Corporation.
2
ARTICLE VIII.
A director of this Corporation shall, to the fullest extent permitted by the General Corporation Law as it now exists or as it may hereafter be amended, not be personally liable to this Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to this Corporation or its stockholders, (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the General Corporation Law, or (iv) for any transaction from which the director derived any improper personal benefit. If the General Corporation Law is amended, after approval by the stockholders of this Article, to authorize any action by the Corporation which further eliminates or limits the personal liability of directors, then the liability of a director of this Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law, as so amended.
Any amendment, repeal or modification of this Article VIII, or the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with this Article VIII, shall not adversely affect any right or protection of a director of this Corporation existing at the time of such amendment, repeal, modification or adoption.
ARTICLE IX.
The Corporation shall, to the fullest extent permitted by the provisions of Section 145 of the General Corporation Law, as the same may be amended and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all of the expenses, liabilities, or other matters referred to in or covered by said section, and the indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any Bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.
If and to the extent that the Corporation may from time to time be or become subject to certain provisions of the California General Corporation Law (“ CGCL ”) pursuant to operation of Section 2115 thereof, then, as authorized by Section 317(g) of CGCL, for the duration of any such period, the Corporation is authorized to indemnify officers, directors, employees, and agents of this Corporation (and any other person to which applicable law permits this Corporation to provide indemnification) in excess of that which is otherwise permitted under Section 317 of the CGCL, subject only to the limits created by applicable Delaware law (statutory or non-statutory).
Any amendment, repeal or modification of this Article IX, or the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with this Article IX, shall not adversely affect any right or protection existing at the time of such amendment, repeal, modification or adoption.
ARTICLE X.
Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws may provide. The books of this Corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of this Corporation.
ARTICLE XI.
The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.
* * *
3
Exhibit 5.1
1000 Fifth Street | PO Box 5025 | |
Suite 200 – P2 | Asheville, NC 28813 | |
Miami Beach, FL 33139 | Phone: 786.273.915 2 | www.eilerslawgroup.com |
October 6, 2017
RE: Reviv3 Procare Company Registration Statement on Form S-1
Gentlemen:
I have been retained by Reviv3 Procare Company, a Delaware corporation (the "Company"), in connection with the Registration Statement (the "Registration Statement"), on Form S-1 to be filed by the Company with the U.S. Securities and Exchange Commission relating to the resale of 3,590,532 shares of the common capital stock of the Company, par value $0.001 (the “Distribution Shares”) to be distributed upon subscription to the underlying Prospectus. You have requested that I render my opinion as to whether or not the securities issued and addressed in the Registration Statement, when sold in the manner referred to in the Registration Statement, will be legally issued, fully paid, and non-assessable. In connection with the request, I have examined the following:
1. | Certificate of Incorporation of Reviv3 Procare Company |
2. | Articles of Amendment of Reviv3 Procare Company; |
3. | The Bylaws of Reviv3 Procare Company; |
4. | A current shareholder listed for Reviv3 Procare Company; |
5. | The subscription agreements and proof of payment of the selling shareholders; |
6. | The Registration Statement; and |
7. | Unanimous consent resolutions of the Company's Boards of Directors, as they relate to private placements, issuances, and the Registration Statement; |
In my examination, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, and conformity with the originals of all documents submitted to me as copies thereof, and I have made no independent verification of the factual matters as set forth in such documents or certificates. In addition, I have made such other examinations of law and fact as I have deemed relevant in order to form a basis for the opinion hereinafter expressed.
Based on the above examination, I am of the opinion that the issuance 3,590,532 shares are validly issued as of October 3, 2017 and are validly issued, fully paid and non-assessable under the corporate laws of the state of Delaware and the Bylaws of the Company when resold in a manner referred to in the Registration Statement. Further, I am of the opinion that Reviv3 Procare Company has approximately 75 shareholders holding 40,505,047 shares validly issued, fully paid and non-assessable.
This opinion is based on Delaware general corporate law, including statutory provisions, applicable provisions of the state Delaware constitution and reported judicial decisions interpreting those laws. I express no opinion, and none should be inferred, as to any other laws, including, without limitation, laws of any other state.
The opinions set forth herein are subject to the following qualifications: (a) I have made no independent verification of the factual matters as set forth in the documents or certificates reviewed, and (b) the opinions set forth herein are limited to the matters expressly set forth in this opinion letter, and no opinion is to be implied or may be inferred beyond the matters expressly so stated.
We hereby consent to the use of our opinion as herein set forth as an exhibit to the Registration Statement and to the use of our name under the caption “Legal Matters” in the prospectus forming a part of the Registration Statement.
Sincerely,
/s/ William Robinson Eilers | |
William Robinson Eilers, Esq. |
Exhibit 10.1
REVIV3 PROCARE
CONTRIBUTION AGREEMENT
This Contribution Agreement (“ Agreement ”), dated as of June 1, 2015, is made by and between REVIV3 PROCARE, LLC, a Delaware limited liability company (“ Transferor ”), and REVIV3 PROCARE COMPANY, a Delaware corporation (“ Transferee ”).
WHEREAS, Transferor and Transferee desire to enter into this Agreement pursuant to which Transferor will convey certain assets and liabilities to Transferee, and Transferee will issue shares of its capital stock to Transferor, all on the terms and subject to the conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1. Contribution of Assets . On the terms and subject to the conditions set forth in this Agreement, each Transferor hereby contributes, transfers, assigns, conveys and delivers to Transferee, and Transferee does hereby acquire and accept from each Transferor, all right, title and interest in, to and under the assets used in, or related to, the development, production, marketing and distribution of hair and beauty products (the “ Business ”), which are used or held for use by such Transferor in connection with the Business (the “ Assumed Assets ”), free and clear of liens and encumbrances, including without limitation, the assets described on the Assumed Assets Schedule . Notwithstanding any provision in this Section 1 to the contrary, the Assumed Assets shall expressly exclude all of the assets set forth on the Excluded Assets Schedule hereto.
2. Assumed Liabilities .
(a) On the terms and subject to the conditions set forth in this agreement, Transferee hereby assumes, and shall perform, pay and discharge all of the liabilities and obligations of the Transferor set forth on Assumed Liabilities Schedule (collectively, the “ Assumed Liabilities ”). Nothing contained herein shall prevent Transferee or its affiliates from contesting in good faith any of the Assumed Liabilities with any third-party obligee.
(b) Each Transferor acknowledges and agrees that the Assumed Liabilities are the only liabilities and obligations related to the Business which Transferee is assuming hereunder, and that such Transferor is retaining, and is and shall be liable for all liabilities and obligations relating to the Business, other than the Assumed Liabilities.
3. Consideration . As consideration for the contribution of the Assumed Assets from Transferor, Transferee agrees to issue to Transferor an aggregate of Twenty Eight Million (28,000,000) shares of Common Stock of Transferee, comprising approximately 70% of the issued and outstanding shares of capital stock of Transferee on the date hereof.
4. Representations and Warranties of the Transferor .
(a) Organization of Transferor . Transferor is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware.
1 |
(b) Authority . Transferor has all requisite power and authority to execute and deliver this Agreement, to carry out its obligations hereunder, and to consummate the transactions contemplated hereby. Transferor has obtained all necessary approval as a limited liability company for the execution and delivery of this Agreement, the performance of its obligations hereunder, and the consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by Transferor, and (assuming due authorization, execution and delivery by Transferee) shall constitute such Transferor’s, legal, valid and binding obligation, enforceable against it in accordance with its terms, as applicable.
(c) Ownership and Transfer of Assets . Transferor has valid, good and marketable title to, or in the case of leased or subleased Assumed Assets, valid and subsisting leasehold interests in, all of the Assumed Assets, and such Assumed Assets are free and clear of all liens and encumbrances. Transferor has the unrestricted right to contribute, sell, transfer, assign, convey and deliver to Transferee all right, title and interest in and to, or in the case of leased or subleased Assumed Assets, all right, title and interest in and to the leasehold interest relating to, the Assumed Assets without penalty or other adverse consequences. The Assumed Assets comprise all of the properties and assets (whether tangible or intangible) necessary for the conduct of the Business as presently conducted (or presently intended to be conducted).
5. Representations and Warranties of the Transferee .
(a) Organization of Transferee . Transferee is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.
(b) Authority . Transferee has all requisite power and authority to execute and deliver this Agreement, to carry out its obligations hereunder, and to consummate the transactions contemplated hereby. Transferee has obtained all necessary approval as a limited liability company for the execution and delivery of this Agreement, the performance of its obligations hereunder, and the consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by Transferee and (assuming due authorization, execution and delivery by Transferor) shall constitute Transferee’s legal, valid and binding obligation, enforceable against it in accordance with its terms.
6. Employee Matters .
(a) Transfer of Employees . On the date hereof, Transferor shall hire certain of Transferor’s employees, all of whom are listed on Employee Schedule (collectively, the “ Transferred Employees ”). The Transferred Employees shall be employed by Transferee on terms and conditions offered to such Transferred Employees by Transferee.
7. Further Assurances .
(a) Transferor and Transferee each agree to execute or cause their subsidiaries to execute any and all documents and instruments of transfer, assignment, assumption or novation, bills of sale, endorsements, deeds and other instruments of conveyance and transfer with respect to the Assumed Assets effecting the sale, transfer, assignment and conveyance of the Assumed Assets to Transferee, and to perform such other acts as may be reasonably necessary or expedient to further the purposes of this Agreement and the transactions contemplated by this Agreement. Transferee further agrees to execute and deliver to Transferor such undertakings of assumption as such Transferor may reasonably request to reflect Transferee’s assumption of the Assumed Liabilities.
2 |
(b) This Agreement shall not constitute an assignment of any claim, asset, right, contract, permit or license if the attempted assignment thereof without the consent of the other party thereto would constitute a material breach thereof or in any way adversely and materially affect the rights of either Transferor thereunder. If such consent is not obtained, or if any attempted assignment thereof would be ineffective or would adversely and materially affect the rights of such Transferor thereunder so that Transferee would not in fact receive all such rights, then (a) only the proceeds of such claim, asset, right, contract, permit or license shall be deemed to have been transferred to Transferee pursuant hereto and such Transferor shall otherwise retain such claim, asset, right, contract, permit or license, and (b) Transferor hereby engages Transferee, and Transferee hereby accepts the engagement, to act as the attorney-in-fact of such Transferor in order to obtain for Transferee the benefit of such claim, asset, right, contract, permit, franchise or license. From and after the date hereof, (i) Transferor shall use its best efforts to obtain or satisfy all such consents, approvals, authorizations, notices, filings, exemptions and other requirements necessary, appropriate, and material for the transfer of the Assumed Assets and the assumption of the Assumed Liabilities contemplated hereby, (ii) to the extent that the MSG Contract (as defined in the Assumed Assets Schedule ) is not assignable by either Transferor after complying with the procedures set forth in subsection (i) above, such Transferor shall use its best efforts to subcontract all services and rights contemplated thereunder to Transferee, and (iii) Transferor shall not provide any services under the MSG Contract or otherwise engage in, directly or indirectly, any business that competes with the Business.
8. Entire Agreement . This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, representations and warranties and agreements, both written and oral, with respect to such subject matter.
9. Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.
10. No Third-Party Beneficiaries . This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.
11. Headings . The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.
12. Amendment and Modification; Waiver . This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
3 |
13. Governing Law; Submission to Jurisdiction . This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdiction other than those of the State of Delaware. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States or the courts of the State of California in each case located in the city of Los Angeles and County of Los Angeles, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by mail to such party’s address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.
14. Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
[SIGNATURE PAGE FOLLOWS]
4 |
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
REVIV3 PROCARE, LLC | ||
By: | /s/ Roger Davis | |
Name: | Roger Davis | |
Title: | Managing Director | |
REVIV3 PROCARE COMPANY | ||
By: | /s/ Roger Davis | |
Name: | Roger Davis | |
Title: | Chief Executive Officer |
5 |
ASSUMED ASSETS SCHEDULE
A. | Intangible Assets |
All of the following whether arising under the laws of the United States or of any foreign or multinational jurisdiction: (i) inventions (whether patentable or unpatentable), all improvements thereto, patents, patent applications (including patents issued thereon) and statutory invention registrations, including reissues, divisions, continuations, continuations in part, substitutions, renewals, extensions and reexaminations of any of the foregoing, and all rights in any of the foregoing provided by international treaties or conventions; (ii) trademarks, service marks, trade names, service names, trade dress, logos and other source or business identifiers, including all goodwill associated with any of the foregoing, and any and all common law rights in and to any of the foregoing, registrations and applications for registration of any of the foregoing, all rights in and to any of the foregoing provided by international treaties or conventions, and all reissues, extensions and renewals of any of the foregoing; (iii) Internet domain names; (iv) copyrightable works, copyrights, moral rights, mask work rights, database rights and design rights, whether or not registered, and all registrations and applications for registration of any of the foregoing, and all rights in and to any of the foregoing provided by international treaties or conventions; (v) trade secrets and confidential business information (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals); (vi) copies and tangible embodiments of any of the foregoing (in whatever form or medium); (vii) licenses and other rights to any of the foregoing; (viii) related ownership, use and other intellectual property and intangible asset rights in and to any of the foregoing (including the right to sue for past, present and future infringements or misappropriations thereof); and (ix) any other intellectual property rights of Transferor, whether registrable or unregistrable.
B. | Tangible Assets |
CASH and CASH EQUIVALENTS . The Balance as of the 31st day of May 2015:
Wells Fargo LLC Checking | $ | 798.81 | ||
Wells Fargo LLC Savings | $ | 1000.83 | ||
Wells Fargo OPS Checking | $ | 4932.98 | ||
Wells Fargo OPS Savings | $ | 500.41 | ||
Total Cash and Cash Equivalents | $ | 7233.03 |
CURRENT ASSETS .
ACCOUNTS RECEIVABLE . The balance of the Accounts Receivable as of the 31st day of May 2015:
Accounts Receivable | $ | 16,369.60 |
S- 1 |
INVENTORY . The Stock Value and Unit availability count per the REVIV3 Procare Inventory Report as of the 31st day of May 2015:
Product Name | StockValue | Available | ||||||
1.7oz/50ml 12 Pack Shipper - Z65715 | $ | 39.05 | 55 | |||||
1.7oz/50ml BOOST - Biotin Cellular Complex | $ | 8,906.48 | 1,497 | |||||
1.7oz/50ml BOOST - BOX - NSTE w/False Top & Bottom - 2 X 1.375 X 6.125 - SBS/0.02 - 5 Color + 1 Foil - Emboss, Spot UV and Soft Touch - PO55347 | $ | 3,590.94 | 5,984 | |||||
10.1oz/300ml 12 Pack Shipper - Z65719 | $ | 110.96 | 292 | |||||
10.1oz/300ml PREP - 50mmX205mm White LDPE Coated Matte Tube w/CC 50mm Glossy Flip Top Cap & Foil Seal - 3 Color Screen Printed | $ | 4,054.04 | 11,001 | |||||
10.1oz/300ml PREP - Cleanser/Shampoo | $ | 6,800.91 | 2,913 | |||||
10.1oz/300ml PREP Label - 1.5” Circular Folded Onsert Label 6 Panel - Size 6.32“X1.5” - 60# Gloss Paper/White BOPP Base - Permanent Adhesive – Gloss Overlaminate - 3” Core - 2,500 Labels Per Roll - Off Bottom #2 | $ | 781.05 | 12,300 | |||||
10.1oz/300ml PRIME - 50mmX205mm White LDPE Coated Matte Tube w/CC 50mm Glossy Flip Top Cap & Foil Seal - 5 Color Screen Printed | $ | 4,477.33 | 10,889 | |||||
10.1oz/300ml PRIME - Moisture+ Conditioner | $ | 7,390.04 | 3,327 | |||||
10.1oz/300ml PRIME Label - 1.5” Circular Folded Onsert Label 6 Panel - Size 6.32“X1.5” - 60# Gloss Paper/White BOPP Base - Permanent Adhesive - Gloss Overlaminate - 3” Core – 2,500 Labels Per Roll - Off Bottom #2 | $ | 789.37 | 12,431 | |||||
2.6oz/75ml TREAT - 24-410 White Smooth Extended Straight Nozzle Sprayer 0.14cc w/4.843"-123mm Dip Tube - SS Spring - Gasket | $ | 1,580.00 | 10,000 | |||||
2.6oz/75ml TREAT - Custom Mold 24/410 35.69mm X 123.24mm 3oz. White Cylinder Soft Touch Bottle - 4 Color Screen Print | $ | 2,436.17 | 10,236 | |||||
2.6oz/75ml TREAT - Micro-Activ3 Treatment Spray | $ | 643.78 | 411 | |||||
2.6oz/75ml TREAT Label-V2 - 1.75” Rectangular Folded Onsert Label 6 Panel - Size 5.0625“X1.75” - 60# Gloss Paper/White BOPP Base - 3 Colors - Permanent Adhesive – Gloss Overlaminate - 3” Core - 2,500 Labels Per Roll – Off Bottom #2 | $ | 21.30 | 300 | |||||
25.4oz/750ml 12 Pack Shipper - Z65720 | $ | 40.15 | 55 | |||||
25.4oz/750ml PREP - Cleanser/Shampoo | $ | 1,987.41 | 357 | |||||
25.4oz/750ml PREP - Cleanser/Shampoo – | ||||||||
Product & Fill - ES43-041A | $ | 22.27 | 12 | |||||
25.4oz/750ml PREP - Custom Mold 24/410 70mmX240mm White HDPE Cylinder Soft Touch Bottle with Logo Embossing – 3 Color Silk Screen | $ | 908.23 | 2,028 | |||||
25.4oz/750ml PREP - Custom Mold 24/410 70mmX240mm White HDPE Cylinder Soft Touch Bottle with Logo Embossing – 3 Color Silk Screen | $ | 22.27 | 3,397 |
S- 2 |
Product Name | StockValue | Available | ||||||
25.4oz/750ml PRIME - Custom Mold 24/410 70mmX240mm White HDPE Cylinder Soft Touch Bottle with Logo Embossing – 5 Color Silk Screen | $ | 1,179.93 | 1,968 | |||||
25.4oz/750ml PRIME - Moisture+ Conditioner | $ | 2,348.99 | 459 | |||||
5.1oz/150ml 12 Pack Shipper - Sprayer - Z65717 | $ | 234.93 | 573 | |||||
5.1oz/150ml 12 Pack Shipper - Tube - Z65716 | $ | 216.00 | 540 | |||||
5.1oz/150ml MEND - 38mmX180mm White LDPE Coated Matte Tube w/CC 50mm Glossy Flip Top Cap & Foil Seal - 4 Color Screen Printed | $ | 3,008.88 | 9,552 | |||||
5.1oz/150ml MEND - Deep Repair Hair Masque | $ | 2,408.58 | 1,588 | |||||
5.1oz/150ml MEND Label - 1.75” Rectangular Folded Onsert Label 6 Panel - Size 5.0625“X1.75” - 60# Gloss Paper/White BOPP Base - 3 Colors – Permanent Adhesive - Gloss Overlaminate – 3” Core - 2,500 Labels Per Roll - Off Bottom #2 | $ | 120.52 | 688 | |||||
5.1oz/150ml MEND Label-V2 - 1.75” Rectangular Folded Onsert Label 6 Panel - Size 5.0625“X1.75” – 60# Gloss Paper/White BOPP Base - 3 Colors – Permanent Adhesive - Gloss Overlaminate - 3” Core - 2,500 Labels Per Roll - Off Bottom #2 | $ | 710.00 | 10,000 | |||||
5.1oz/150ml PREP - 38mmX180mm White LDPE Coated Matte Tube w/CC 50mm Glossy Flip Top Cap & Foil Seal - 3 Color Screen Printed | $ | 2,937.91 | 9,959 | |||||
5.1oz/150ml PREP - Cleanser/Shampoo | $ | 61.92 | 45 | |||||
5.1oz/150ml PREP Label-V2 - 1.75” Rectangular Folded Onsert Label 6 Panel - Size 5.0625” X1.75” – 60# Gloss Paper/White BOPP Base - 3 Colors – Permanent Adhesive - Gloss Overlaminate – ” Core - 2,500 Labels Per Roll - Off Bottom #2 | $ | 24.85 | 350 | |||||
5.1oz/150ml PRIME - 38mmX180mm White LDPE Coated Matte Tube w/CC 50mm Glossy Flip Top Cap & Foil Seal - 5 Color Screen Printed | $ | 3,223.37 | 9,622 | |||||
5.1oz/150ml PRIME Label-V2 - 1.75” Rectangular Folded Onsert Label 6 Panel - Size 5.0625“X1.75” – 60# Gloss Paper/White BOPP Base - 3 Colors – Permanent Adhesive - Gloss Overlaminate – 3” Core - 2,500 Labels Per Roll - Off Bottom #2 | $ | 24.85 | 350 | |||||
5.1oz/150ml TREAT - 24-410 White Smooth Extended Straight Nozzle Sprayer 0.14cc w/5.984"-152mm Dip Tube - SS Spring - Gasket | $ | 677.99 | 4,913 | |||||
5.1oz/150ml TREAT - Custom Mold 24/410 40.84mm X 151.33mm 5oz. White Cylinder Soft Touch Bottle - 4 Color Screen Print | $ | 17.21 | 70 | |||||
5.1oz/150ml TREAT - Micro-Activ3 Treatment Spray | $ | 5,769.52 | 2,107 | |||||
5.1oz/150ml TREAT Label-V2 - 1.75” Rectangular Folded Onsert Label 6 Panel - Size 5.0625“X1.75” – 60# Gloss Paper/White BOPP Base - 3 Colors – Permanent Adhesive - Gloss Overlaminate – 3” Core - 2,500 Labels Per Roll - Off Bottom #2 | $ | 355.00 | 5,000 | |||||
6.8oz/200ml 12 Pack Shipper - Z65718 | $ | 399.30 | 1,210 |
S- 3 |
Product Name | StockValue | Available | ||||||
6.8oz/200ml PROTECT - 24/410 200ml Non-Aerosol Tubular White Soft Touch HDPE Co-Ex Bottle (#5286) - 5 Pass Color Screen Print | $ | 127.04 | 195 | |||||
6.8oz/200ml PROTECT - Thermal Protector | $ | 4,172.31 | 2,502 | |||||
6.8oz/200ml THICKEN - Thickening Spray | $ | 4,991.11 | 2,527 | |||||
6.8oz/200ml THICKEN/PROTECT - 200ml Angular Non-Aerosol Overcap - White Matte COPP (#8324) | $ | 60.89 | 451 | |||||
D2C Brochure | $ | 4,841.68 | 4,474 | |||||
D2C SHIPPER BOX - CAD#10584 - 17 X 11 1/16 X 2 1/8 - White 2 sides w/4 Color Print exterior and Green Floodcoat interior PMS 5487c with reverse print- Z66988-1 | $ | 4,311.15 | 2,080 | |||||
Introductory Kit 30 Day | $ | 3,351.49 | 632 | |||||
Introductory Kit 30 Day (V2) - INSERT – Lock End Sleeve w/Cutouts - 7.28125 X 0.75 X 7.875 - SBS/0.02 - W/0.02 - PO58542 | $ | - | 57 | |||||
Introductory Kit 30 Day (V2) - INSERT - Lock End Sleeve w/Cutouts - 7.28125 X 0.75 X 7.875 - SBS/0.02 - W/0.02 - PO58542 | $ | - | 300 | |||||
Introductory Kit 30 Day - BOX - NSTE w/False Bottom and Diecut Holes - 7.375 X 1.625 X 8 - SBS/0.02 - 5 Color - Spot UV and
Soft Touch - PO55134 |
$ | 2,582.16 | 3,380 | |||||
Introductory Kit 30 Day - INSERT - CAD# 10584B - 22 5/8 X 16 - White with 100% Floodcoat Green PMS 5487c - Z66535-1 | $ | 3,354.74 | 2,222 | |||||
Introductory Kit 30 Day - INSERT - Die Cut Insert - 7.3125 X 1.5 X 4.75 - SBS/0.02 – White - PO55136 | $ | - | 3,443 | |||||
Introductory Kit 30 Day - Italian Version – BOX - NSTE w/False Bottom and Diecut Holes - 7.375 X 1.625 X 8 – SBS/0.02 - 5 Color - Spot UV and Soft Touch - PO55134 | $ | 145.91 | 191 | |||||
Introductory Kit 30 Day - WINDOW INSERT – 7.3181 X 7.9795 - P056203 - SBS/0.02 – 6 Colors + UV Coating (6/1) - 330344/522746 | $ | 579.12 | 2,979 | |||||
Introductory Kit 30 Day ENGLISH (V2) - BOX – NSTE w/Diecut Holes & Catlocks - 7.3375 X 1.625 X 8 - SBS/0.20 - W 0.02 - 5 Color - Spot UV and Soft Touch - PO58850 | $ | 271.80 | 300 | |||||
Introductory Kit 30 Day ITALIAN (V2) - BOX – NSTE w/Diecut Holes & Catlocks - 7.3375 X 1.625 X 8 - SBS/0.20 - W 0.02 - 5 Color – Spot UV and Soft Touch - PO58850 | $ | 121.40 | 134 | |||||
KIT - 30 Day Trial Kit | $ | 3,436.08 | 468 | |||||
Kit Box 12 Pack Shipper - Z65721 | $ | 390.00 | 650 | |||||
PREP PUMP - 24/410, 2cc, Custom Color Yellow/Green 24mm Pump (PMS368C) | $ | 461.06 | 3,129 | |||||
PREP PUMP - 24/410, 2cc, Custom Color Yellow/Green 24mm Pump (PMS368C) | $ | 22.27 | 12 | |||||
PRIME PUMP - 24/410, 2cc, Custom Color | ||||||||
Gray/Green 24mm Pump (5487C) | $ | 461.35 | 3,131 | |||||
Product Information Book | $ | 674.60 | 4,726 | |||||
Tote Bag - White - 2 Color Logo Screen | ||||||||
Print - 15 x 13.5 x 4.25 - EROS - SM7329 | $ | 80.83 | 52 | |||||
Total Inventory Value | $ | 102,758.51 |
S- 4 |
NOTES RECEIVABLE . The balance of the Notes Receivable as of the 31st day of May 2015:
Notes Receivable | $ | 5000.00 |
PREPAYMENTS . The balance of the Prepayments as of the 31st day of May 2015:
Prepayments | $ | 141.13 | ||
Total Current Assets | $ | 130,366.95 | ||
O THER NON-CURRENT ASSETS. |
||||
DEPOSITS . The balance of the Deposits as of the 31st day of May 2015: | ||||
Deposits | $ | 9455.00 | ||
Total Other Non-Current Assets | $ | 9455.00 | ||
TOTAL ASSETS | $ | 147,054.98 |
C. | Transferred Employees |
All payroll and benefit obligations with respect to the Transferred Employees.
D. | Assumed Contracts |
1. | CARBONARI S.R.L Distribution Agreement . Distribution Agreement effective as of the 10th of July between REVIV3 Procare, LLC and Carbonari SRL (Distributor). |
2. | DEPASQUALE SALON SYSTEMS Distribution Agreement . Distribution Agreement made effective as of the 1st day of August 2014 between REVIV3 Procare, LLC and DePasquale Salon Systems (Distibutor). |
3. | First Amendment to Distribution Agreement Between REVIV3 PROCARE LLC and DEPASQUALE SALON SYSTEMS. The letter serves as a First Amendment to the Distribution Agreement dated as of the 1st day of August 2014 between REVIV3 Procare LLC and DePasquale Salon Systems. [Both parties mutually agreed to the following changes of SECTION V. DISTRIBUTOR’S ACTIVITIES and RESPONSIBILITIES – Subsection A6, SECTION VII. PRICING and PAYMENT – Subsection B, SECTION IX. PROMOTION – Subsection B, SECTION XIV. TERMINATION – Subsection B.] |
S- 5 |
4. | FINE LINE Distribution Agreement . The Distribution Agreement made as of the 1st of June 2015 by and between REVIV3 Procare, LLC and FineLine Distributors. |
5. | PENKO Distribution Agreement . The Distribution Agreement made as of the 1st day of August 2014 by and between REVIV3 Procare, LLC and Penko Beauty LLC. |
6. | PRINCESS PROFESSIONAL Distribution Agreement . The Distribution Agreement made as of the 30th day of October 2014 by and between REVIV3 Procare, LLC and Princess Beauty Supply LLC, DBA Princess Professional Salon and Spa Service. |
7. | TOTAL IMAGE BEAUTY Distribution Agreement . The Distribution Agreement as of the 1st day of February 2015 by and between REVIV3 Procare, LLC and Total Image Beauty. |
8. | LEASE Agreement . The Lease Agreement made as of the 1st day of July 2014 by and between CWCA ARCHIBALD 69, LLC and REVIV3 Procare, LLC for the building located at 9447 London Way, Rancho Cucamonga, California. |
ASSUMED LIABILITIES SCHEDULE
All liabilities and obligations in respect of any Assumed Assets, but only to the extent that such liabilities and obligations are required to be performed after the date of this Agreement, were incurred in the ordinary course of business and do not relate to any failure to perform, improper performance, warranty or other breach, default or violation by any Transferor on or prior to the date hereof.
S- 6 |
EXCLUDED ASSETS SCHEDULE
Transferor will retain and not contribute, convey, assign or transfer, and Transferee will not acquire, the following (collectively, the “ Excluded Assets ”):
(i) Company records, limited liability company agreement, certificate of organization, minute books, unit transfer records and other records related to the formation and organization of Transferor;
(ii) Any recovery of cash, assets or other property received by Transferor that represents a return of or on any amounts or obligations previously paid or incurred by Transferor in connection with any Excluded Liability;
(iii) (A) Benefit plans and contracts of insurance of Transferor for employee group medical, dental and life insurance plans and (B) all insurance policies of Transferor, to the extent that the parties mutually agree that any such items should not be transferred to Transferee; and
(iv) All rights of Transferor under this Agreement.
S- 7 |
EMPLOYEE SCHEDULE
Roger Davis
Chris Go
[OTHER NAMES]
S-8
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the use of our report dated October 6, 2017, on the financial statements of Reviv3 Procare Company as of May 31, 2017 and 2016 and for each of the two years in the period ended May 31, 2017, included herein on the registration statement of Reviv3 Procare Company on Form S-1, and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ Salberg & Company, P.A. | |
SALBERG & COMPANY, P.A. | |
Boca Raton, Florida | |
October 6, 2017 |